

DESCRIPTION

Title of Invention: METHOD FOR PRODUCING CD3-POSITIVE CELL
[Technical Field]
[0001]

5 The present invention relates to a production method or
an expansion culture method of CD3-positive cells (or CD3-
positive CD197-positive cells), including a step of culturing
CD3-positive cells in the presence of a CD3/TCR complex agonist,
fibronectin or a variant thereof, and a CD30 agonist, and a kit
10 for expansion culture of CD3-positive cells. The present
invention also relates to a method for maintaining CD3-positive
cells as CD3-positive CD197-positive cells, including a step of
stimulating a CD30 signal in the CD3-positive cells, and a kit
for maintaining CD3-positive cells as CD3-positive CD197-
15 positive cells.

[0002]

(Background of the Invention)

Immunotherapy has been clarified to show a strong life-
prolonging effect even on cancers for which conventional
20 treatments are not effective and is becoming a leading therapy
in cancer treatment. CART therapy including transfer of
autologous T cells transfected with anti-CD19 chimeric antigen
receptor (CAR) gene shows a high complete remission rate for B
cell malignancies, and the FDA approved two CART therapies for
25 B-cell acute lymphoblastic leukemia and diffuse large B-cell
lymphoma in 2017. In addition, many clinical trials are
underway for TCR-T cell therapy in which a T cell receptor
(TCR) gene that recognizes cancer cell antigen is introduced.
While these genetically-modified T cell therapies using
30 patients' own (self) T cells show extremely superior clinical
results, they involve transport, gene modification, cell
culture, and the like of T cells. Such complicated processes
requiring several weeks or more make suppression of costs and
quality control difficult. Moreover, since they lead to the
35 loss of treatment opportunities for patients with fast-growing

cancer, the development of an off-the-shelf allogenic T cell therapy is strongly demanded. As a method for expansion culture of T cells collected from patients, a method for producing CD8-positive Tc1 lymphocytes or CD8-positive Tc2 lymphocytes by contacting a T cell population with an anti-CD3 agonist antibody and an anti-CD30 agonist antibody (patent document 1), a method for expansion culture of tumor-specific T cells by obtaining a T cell population from a cancer patient and contacting the T cell population with an anti-CD3 agonist antibody, an anti-CD28 antibody, and a VEGF inhibitor (patent document 2) have been reported so far. However, T cells derived from healthy donor or patients have limited proliferative capacity, and the number of genetically modified T cells that can be produced from T cells that can be recovered by a single apheresis is limited. In addition, it has been reported that expansion culture of T cells by TCR stimulation causes a transient increase in the expression of CCR7 (CD197), which is a cell surface marker of naive cells and memory T cells, followed by disappearance within several days thereafter (non-patent document 1). In addition, it has been reported that being a memory T cell ("T cell persistence") is important for in vivo antitumor activity, and that a high in vivo antitumor effect was observed by increasing the number of CART cells to be administered, which is a memory T cell (non-patent document 2). Therefore, low CD197 expression in the cell population obtained by expansion culture of T cells was not suitable for cancer treatment.

[0003]

On the other hand, since T cells differentiated from pluripotent stem cells such as iPS cell, ES cell, and the like (differentiated T cells) are made from pluripotent stem cells that can theoretically proliferate infinitely, modified T cells can be produced infinitely in theory. However, a method for expansion culture of iPS cells while maintaining pluripotency requires high cost and involves technical difficulties.

Therefore, a method for obtaining differentiated T cells, particularly CD197-positive T cells, by proliferating a large number of iPS cells has a limitation. As a result, another approach to obtain a large number of T cells, particularly
5 CD197-positive T cells, has been demanded.

[Document List]

[Patent documents]

[0004]

patent document 1: WO 2003/038062

10 patent document 2: US-A-2014/0255368

[Non-patent document]

[0005]

non-patent document 1: Sallusto et al., Eur. J. Immunol. vol. 29, 2037-2045, 1999

15 non-patent document 2: Kaartinen et al., Cytotherapy vol. 19, 689-702, 2017

[Summary of Invention]

[Technical Problem]

[0006]

20 The present invention aims to stably supply differentiated T cells, particularly CD197-positive T cells, and provides a production method, an expansion culture method, and a kit for expansion culture of CD3-positive cells with a T cell marker CD3 expressed on a cell membrane. Another object
25 of the present invention is to provide a method for maintaining CD197-positive T cells and a kit for maintaining CD197-positive T cells.

[Solution to Problem]

[0007]

30 The present inventors have conducted intensive studies in an attempt to achieve the objects and found that CD8-positive T cells obtained from iPS cells transfected with TCR gene (iPS cell-derived CD8-positive T cells) can be efficiently proliferated by culturing the T cells in a medium containing an
35 anti-CD30 agonist antibody on a culture container in which

anti-CD3 agonist antibody and RetroNectin (registered trade mark) are immobilized. Furthermore, they have confirmed that the proliferation efficiency of the T cells and the antigen-specific cytotoxic activity are not affected even when the iPS
5 cell-derived CD8-positive T cells are repeatedly proliferated by the culture method. In addition, they have found that, when the iPS cell-derived CD8-positive T cells are cultured using an anti-CD30 agonist antibody, the expression rate of CD197 becomes high as compared to the non-use of the anti-CD30
10 agonist antibody and the proliferated T cells are present as central memory T cells. Similar to the iPS cell-derived CD8-positive T cells, moreover, human peripheral blood-derived CD8-positive T cells and iPS cell-derived CD8-positive T cells transfected with anti-CD19-CAR gene (iPS cell-derived anti-
15 CD19-CART cells) could also be proliferated efficiently by adding an anti-CD30 agonist antibody to the medium on a culture container in which anti-CD3 agonist antibody/RetroNectin (registered trade mark) are immobilized. Furthermore, they have found that when the human peripheral blood-derived CD8-
20 positive T cells or the iPS cell-derived anti-CD19-CART cells are cultured using an anti-CD30 agonist antibody, the expression of CD197 is maintained for a long term and the human peripheral blood-derived CD8-positive T cells can survive in vivo for a long term as compared to the non-use of the anti-
25 CD30 agonist antibody. Based on the above findings, they have completed the present invention.

[0008]

Accordingly, the present invention provides the following.

[1] A method for producing a CD3-positive cell, comprising step
30 (I) of culturing the CD3-positive cell in the presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.

[2] The method of [1], further comprising step (II) of culturing the CD3-positive cell cultured in step (I) in the
35 absence of a CD3/TCR complex agonist and fibronectin or a

variant thereof, and in the presence of a CD30 agonist.

[3] The method of [1] or [2], wherein the CD3-positive cell is derived from a pluripotent stem cell.

[4] The method of [3], wherein the pluripotent stem cell is an
5 iPS cell.

[5] The method of any one of [1] to [4], wherein the CD3-positive cell is a chimeric antigen receptor-expressing CD3-positive cell.

[6] The method of any one of [1] to [5], wherein the CD3-
10 positive cell is a CD3-positive CD8-positive cell.

[7] The method of [6], wherein the CD3-positive CD8-positive cell is a CD3-positive CD8-positive CD4-negative cell.

[8] The method of any one of [1] to [7], wherein the CD3-positive cell is a γ TCR-positive and/or δ TCR-positive cell.

15 [9] The method of any one of [1] to [8], wherein the CD3/TCR complex agonist is a CD3 agonist and/or a TCR agonist.

[10] The method of [9], wherein the CD3 agonist is an anti-CD3 agonist antibody or a binding fragment thereof.

[11] The method of [10], wherein the anti-CD3 agonist antibody
20 or a binding fragment thereof is an anti-CD3 agonist antibody or a binding fragment thereof produced from UCHT1 clone.

[12] The method of [9], wherein the TCR agonist is at least one selected from the group consisting of an anti-TCR antibody or a binding fragment thereof, an HLA/peptide complex or a multimer
25 thereof, and an HLA/superantigen complex or a multimer thereof.

[13] The method of [10] or [11], wherein the anti-CD3 agonist antibody or a binding fragment thereof is immobilized on a culture container.

[14] The method of [13], wherein the anti-CD3 agonist antibody
30 or a binding fragment thereof is immobilized by contacting 1 ng/ml - 50000 ng/ml of the anti-CD3 agonist antibody or a binding fragment thereof with the culture container.

[15] The method of any one of [1] to [14], wherein the fibronectin or a variant thereof is RetroNectin (registered
35 trade mark).

- [16] The method of [15], wherein the RetroNectin (registered trade mark) is immobilized on the culture container.
- [17] The method of [16], wherein the RetroNectin (registered trade mark) is immobilized by contacting 1 - 150 µg/mL of the RetroNectin (registered trade mark) with the culture container.
- [18] The method of any one of [1] to [17], wherein the CD30 agonist is at least one selected from the group consisting of an anti-CD30 agonist antibody or a binding fragment thereof and a CD30 ligand or a binding fragment thereof.
- [19] The method of [18], wherein the anti-CD30 agonist antibody or a binding fragment thereof is contained in the medium.
- [20] The method of [19], wherein a concentration of the anti-CD30 agonist antibody or a binding fragment thereof in the medium of 1 ng/ml - 1000 ng/ml.
- [21] The method of any one of [1] to [20], wherein the medium comprises at least one selected from IL-7, IL-15, IL-18 and IL-21.
- [22] The method of [21], wherein the medium comprises IL-7, IL-15, IL-18 and IL-21.
- [23] The method of [21] or [22], wherein the medium further comprises TL1A and/or IL-12.
- [24] The method of any one of [1] to [23], wherein the CD3-positive cell produced is further CD197-positive.
- [25] A CD3-positive cell obtained by the method of any one of [1] to [24].
- [26] A method for expansion culture of a CD3-positive cell, comprising a step of culturing the CD3-positive cell in the presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.
- [27] A kit for expansion culture of a CD3-positive cell, comprising the following:
- (1) a culture container in which a CD3/TCR complex agonist, and fibronectin or a variant thereof are immobilized, and
 - (2) a medium comprising a CD30 agonist.
- [28] A method for maintaining a CD3-positive cell as a CD3-

positive CD197-positive cell, comprising a step of stimulating a CD30 signal in the CD3-positive cell.

[29] The method of [28], wherein the CD3-positive cell is a CD3-positive CD8-positive cell.

5 [30] The method of [29], wherein the CD3-positive CD8-positive cell is a CD3-positive CD8-positive CD4-negative cell.

[31] The method of any one of [28] to [30], wherein the medium used in the step of stimulation comprises at least one selected from IL-7, IL-15, IL-18 and IL-21.

10 [32] The method of [31], wherein the medium used in the step of stimulation comprises IL-7, IL-15, IL-18 and IL-21.

[33] The method of [31] or [32], wherein the medium used in the step of stimulation further comprises TL1A and/or IL-12.

[34] A kit for maintaining a CD3-positive cell as a CD3-
15 positive CD197-positive cell, comprising a CD30 agonist.

[35] A chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain and an intracellular signal transduction domain, wherein the intracellular signal transduction domain comprises a CD30 intracellular signal
20 transduction domain or a mutant thereof.

[36] A nucleic acid comprising a polynucleotide encoding the chimeric antigen receptor of [35].

[37] A chimeric antigen receptor expression vector comprising the nucleic acid of [36].

25 [38] A chimeric antigen receptor-expressing cell comprising the chimeric antigen receptor expression vector of [37].

[39] The cell of [38], wherein the chimeric antigen receptor expression cell is a CD3-positive cell.

[40] A medicament comprising the cell of [38] or [39].

30 [41] The medicament of [40] for use in the prophylaxis or treatment of a tumor expressing an antigen recognized by the chimeric antigen receptor of [35].

[42] An agent for killing a cell expressing an antigen recognized by the chimeric antigen receptor of [35], wherein
35 the agent comprises the cell of [38] or [39].

[43] The cell of [38] or [39] for use in the prophylaxis or treatment of a tumor expressing an antigen recognized by the chimeric antigen receptor of [35].

[44] Use of the cell of [38] or [39] in producing an agent for
5 the prophylaxis or treatment of a tumor expressing an antigen recognized by the chimeric antigen receptor of [35].

[45] A method for preventing or treating a tumor expressing an antigen recognized by the chimeric antigen receptor of [35], comprising administering the cell of [38] or [39].

10 [Advantageous Effects of Invention]
[0009]

T cells can be efficiently produced or expansion cultured by culturing CD3-positive cells in the presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30
15 agonist. In addition, since the CD3-positive cells produced or expansion cultured by the above-mentioned culture are CD197-positive cells, long-term efficacy is expected when the cells are used for genetically modified T cell therapy. In addition, CD3-positive cells can be maintained for a long term as CD197-
20 positive cells by stimulating the CD30 signal of the cells.

[Brief Description of Drawings]
[0010]

Fig. 1 shows concentrations suitable for immobilizing anti-CD3 agonist antibody and RetroNectin (registered trade
25 mark) as measured by the ELISA method.

Fig. 2 shows iPSC-derived T cell counts (measured by the ATP amount) 12 days after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 3 shows proliferation curves of iPSC-derived T cells
30 stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) or anti-CD3/CD28 beads. The vertical axis shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

35 Fig. 4 shows proliferation curves of iPSC-derived T cells

for each number of stimulations with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 5 shows the antigen-specific cytotoxic activity of iPSC-derived T cells proliferated by stimulation with
5 immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 6 shows promoted proliferation of iPSC-derived T cells stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) by the addition of
10 an anti-CD30 agonist antibody. The vertical axis shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

Fig. 7 shows the proliferation curves of iPSC-derived T
15 cells that underwent a proliferation test in which the iPSC-derived T cells were stimulated (first stimulation) with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark), or immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30
20 agonist antibody, and then the same stimulation (second stimulation) again after the completion of the test. The vertical axis shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned second stimulation was started.

25 Fig. 8 shows the expression of CD197 and CD45RA on the cell membrane surface of iPSC-derived T cells 7 days after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark), or immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark)
30 and anti-CD30 agonist antibody.

Fig. 9 shows the antigen-specific cytotoxic activity of iPSC-derived T cells proliferated by stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody.

35 Fig. 10 shows proliferation curves of human peripheral

blood-derived CD8-positive T cells stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark), or immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody. The
5 vertical axis shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

Fig. 11 shows the expression of CD197 on the cell membrane surface of human peripheral blood-derived CD8-positive
10 T cells after stimulation with anti-CD3/CD28 beads containing various ILs and anti-CD30 antibody.

Fig. 12 shows the number of human CD8-positive T cells surviving in the blood, spleen and bone marrow of irradiated immunodeficient mice 4 weeks after intravenous transplantation
15 of human peripheral blood-derived CD8-positive T cells after stimulation with anti-CD3/CD28 beads containing various ILs and anti-CD30 antibody.

Fig. 13 shows proliferation curves of iPS cell-derived T cells (iPS-T) and iPS cell-derived anti-CD19-CART cells (iPS-CART anti-CD19) stimulated with immobilized anti-CD3 agonist
20 antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody. The vertical axis shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

Fig. 14 shows proliferation curves of iPS cell-derived anti-CD19-CART cells stimulated with immobilized anti-CD3
25 agonist antibody/RetroNectin (registered trade mark), or immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody. The vertical axis
30 shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

Fig. 15 shows the expression of CD197 on the cell membrane surface of iPS cell-derived anti-CD19-CART cells
35 stimulated with immobilized anti-CD3 agonist

antibody/RetroNectin (registered trade mark), or immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody.

Fig. 16 shows the cytotoxic activity, against CD19-
5 expressing Raji cells, of iPS cell-derived anti-CD19-CART cells stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) by the addition of anti-CD30 agonist antibody.

Fig. 17 shows the cytotoxic activity, against CD19-
10 expressing Raji cells, of iPS cell-derived anti-CD19-CART cells (iCD19-CD30-CART) containing a CD30-derived intracellular domain.

Fig. 18 shows cell proliferation of $\gamma\delta$ T cells (i $\gamma\delta$ T cells) differentiated from non-T cell-derived iPS cells and
15 stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) by the addition of anti-CD30 agonist antibody. The vertical axis shows the cell proliferation ratio, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned
20 stimulation was started.

Fig. 19 shows cell proliferation of anti-CD19-CAR $\gamma\delta$ T cells (iCAR $\gamma\delta$ T cells) stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) by the addition of anti-CD30 agonist antibody. The vertical axis
25 shows cell counts, and the horizontal axis shows the number of days elapsed from the day when the above-mentioned stimulation was started.

Fig. 20 shows the antigen-specific cytotoxic activity of iCD19CAR/IL-15 $\gamma\delta$ T cells proliferated by stimulation with
30 immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 21 shows the effect of increasing the survival days of human CD19-expressing tumor-bearing mice by iCD19CAR/IL-15 $\gamma\delta$ T cells proliferated by stimulation with immobilized anti-
35 CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 22 shows the antitumor effect of iCD19CAR/IL-15 α β T cells proliferated by stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark).

Fig. 23 shows the concentration suitable for immobilizing anti-CD3 agonist antibody (UCHT1) and RetroNectin (registered trade mark) as measured by the ELISA method.

Fig. 24 shows the proliferation rate of iPSC-derived T cells 13 days after stimulation with immobilized anti-CD3 agonist antibody (UCHT1)/RetroNectin (registered trade mark) and anti-CD30 agonist antibody.

[0011]

(Detailed Description of the Invention)

In the present specification, the "gene expression" encompasses both the synthesis of mRNA from a specific nucleotide sequence of the gene (also referred to as transcription or mRNA expression) and the synthesis of protein based on the information of the mRNA (also referred to as translation or protein expression). Unless otherwise specified, the "gene expression" or simple "expression" means expression of protein.

[0012]

In the present specification, "positive" means that a protein or mRNA is expressed in an amount detectable by a method known in the art. Protein can be detected by an immunological assay using an antibody, such as ELISA method, immunostaining method, Western blot method, and flow cytometry. In addition, a reporter protein is expressed together with the protein, and the target protein may be detected by detecting the reporter protein. In addition, the presence of a protein can be detected by detecting the function of the protein (e.g., when the protein is a transcription factor, a gene whose expression is controlled by the protein is detected, and when the protein is an enzyme, a substrate or a product catalyzed by the protein is detected, and the like). mRNA can be detected by, for example, nucleic acid amplification method and/or

nucleic acid detection method such as RT-PCR, microarray, biochip, RNAseq and the like.

[0013]

In the present specification, "negative" means that the expression level of the protein or mRNA is less than the lower limit of detection by all or any of the above-mentioned known methods. The lower limit of detection of protein or mRNA expression may vary depending on each method.

[0014]

In the present specification, the "culture" refers to maintaining, proliferating (growing) and/or differentiating cells in an in vitro environment. "Culturing" means maintaining, proliferating (growing) and/or differentiating cells extra-tissue or ex-vivo, for example, in a cell culture dish or flask.

[0015]

In the present specification, the "expansion culture" means culturing for the purpose of proliferating a desired cell population and increasing the cell number. The increase in cell number may be achieved by increasing the number of cells by proliferation to exceed the decrease in number by death, and it does not require proliferation of all cells in the cell population. The increase in the cell number may be 1.1 times, 1.2 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 30 times, 40 times, 50 times, 100 times, 300 times, 500 times, 1,000 times, 3,000 times, 5,000 times, 10,000 times, 100,000 times, or not less than 1,000,000 times, compared to that before the start of expansion culture.

[0016]

In the present specification, "stimulation" means that a certain substance binds to various receptors and the like to activate a signal pathway at the downstream thereof.

[0017]

In the present specification, "enrich" refers to

increasing the amount of a specific constituent component in a composition such as cell composition and the like, and "enriched" refers to a cell population in which, when used to explain a cell composition, for example, cell population, the amount of a specific constituent component has increased as compared to the proportion of such constituent component in the cell population before the enrichment. For example, a composition such as a cell population and the like can be enriched with respect to a target cell type, and therefore, the proportion of the target cell type increases as compared to that of the target cell present in the cell population before enrichment. The cell population can also be enriched with respect to a target cell type by cell selection or a screening method known in the art. The cell population can also be enriched by the specific selection or screening process described in the present specification. In specific embodiments of the present invention, at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 97%, 98% or 99% of the target cell population is enriched by a method for enriching the target cell population.

[0018]

In the present specification, the "cell population" means two or more cells of the same type or different types. The "cell population" also means a mass of cells of the same type or different types.

[0019]

The present invention provides a production method or an expansion culture method of CD3-positive cells, including a step of culturing CD3-positive cells in the presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist (hereinafter sometimes to be referred to as the production method or expansion culture method of the present invention).

The CD3/TCR complex and CD30 can be respectively stimulated with a CD3/TCR complex agonist and a CD30 agonist.

[0020]

In the production method or expansion culture method of the present invention, the CD3-positive cell to be cultured is not particularly limited as long as it expresses CD3 on the cell membrane. The CD3-positive cell is preferably a CD3-positive CD8-positive cell (CD3-positive CD8-positive CD4-positive cell or CD3-positive CD8-positive CD4-negative cell), more preferably, a CD3-positive CD8-positive CD4-negative cell. Another preferred CD3-positive cell is, for example, a CD3-positive CD4-positive cell (CD3-positive CD4-positive CD8-positive cell or a CD3-positive CD4-positive CD8-negative cell).

The CD3-positive cell to be cultured by the production method or expansion culture method of the present invention may be CD30-positive before culture, or differentiated to be CD30-positive during culture. Therefore, when the CD3-positive cell is CD30-positive before culture, the CD3-positive cell is preferably a CD3-positive CD8-positive CD30-positive cell (CD3-positive CD8-positive CD4-positive CD30-positive cell or CD3-positive CD8-positive CD4-negative CD30-positive cell), more preferably, a CD3-positive CD8-positive CD4-negative CD30-positive cell. Another preferred CD3-positive cell is, for example, a CD3-positive CD4-positive CD30-positive cell (CD3-positive CD4-positive CD8-positive CD30-positive cell or CD3-positive CD4-positive CD8-negative CD30-positive cell).

[0021]

The CD3-positive cell obtained by production or expansion culture by the production method or expansion culture method of the present invention is not particularly limited as long as it expresses CD3 on the cell membrane, and may be, for example, a cell similar to the CD3-positive cell cultured in the production method or expansion culture method of the present invention. The CD3-positive cell after the production or expansion culture is preferably CD197-positive. The CD3-positive cell after the production or expansion culture is further CD197-positive, the cell is specifically a CD3-positive

CD8-positive CD197-positive cell (CD3-positive CD8-positive CD4-positive CD197-positive cell or CD3-positive CD8-positive CD4-negative CD197-positive cell), more preferably, a CD3-positive CD8-positive CD4-negative CD197-positive cell.

5 Alternatively, the cell is a CD3-positive CD4-positive CD30-positive CD197-positive cell (CD3-positive CD4-positive CD8-positive CD30-positive CD197-positive cell or CD3-positive CD4-positive CD8-negative CD30-positive CD197-positive cell).

Among the CD3-positive cells, since the CD197-positive cell is
10 classified into stem cell memory T cell or central memory T cell according to the presence or absence of CD45RA expression, and has high self-proliferation ability that can supply effector T cells, it is suitable for anti-tumor immunity.

The CD3-positive cell after the production or expansion
15 culture is further preferably CD197-positive CD45RA-negative. When the CD3-positive cell after the production or expansion culture is further CD197-positive CD45RA-negative, the cell is specifically a CD3-positive CD8-positive CD197-positive CD45RA-negative cell (CD3-positive CD8-positive CD4-positive CD197-
20 positive CD45RA-negative cell or CD3-positive CD8-positive CD4-negative CD197-positive CD45RA-negative cell), more preferably, a CD3-positive CD8-positive CD4-negative CD197-positive CD45RA-negative cell. Alternatively, the cell is a CD3-positive CD4-positive CD30-positive CD197-positive CD45RA-negative cell
25 (CD3-positive CD4-positive CD8-positive CD30-positive CD197-positive CD45RA-negative cell or CD3-positive CD4-positive CD8-negative CD30-positive CD197-positive CD45RA-negative cell). Among the CD3-positive cells, the CD197-positive CD45RA-negative cell is also particularly called a central memory T
30 cell.

[0022]

CD3 is a molecule that is expressed during the maturation process of T cells, forms a larger complex (CD3/TCR complex) with the T cell receptor (TCR), and is also known as a T cell
35 marker. It is a complex of 4 types of polypeptides of γ , δ , ϵ ,

and ζ chains. The TCR that forms a complex with CD3 is a molecule that transmits a signal into T cells, and examples include a dimer composed of two out of α chain (TCR α), β chain (TCR β), γ chain (TCR γ), and δ chain (TCR δ), a heterodimer (5 $\alpha\beta$ TCR) composed of TCR α and TCR β , a heterodimer ($\gamma\delta$ TCR) composed of TCR γ and TCR δ , and homo dimer composed of the same TCR chains. Like CD3, CD8 is expressed in vivo during the maturation process of T cells and is expressed together with CD4 in the early stages of maturation, but only the expression 10 of CD4 is lost along with the differentiation into cytotoxic T cells. CD8 is a molecule that functions as a co-receptor of the CD3/TCR complex and recognizes MHC class I/antigen peptide, and is a homodimer consisting of α -chain polypeptides or a heterodimer consisting of two types of polypeptides of α - and 15 β -chains. CD4 is expressed in vivo together with CD8 in the early stages of T cell maturation, but only CD8 expression is lost along with differentiates into helper T cells. Like CD8, CD4 also functions as a co-receptor of the CD3/TCR complex, but unlike CD8, it is a molecule that recognizes MHC class 20 II/antigen peptide. CD30 is known as a molecule expressed in activated lymphocytes (T cells and B cells), has 6 cystein-rich pseudo-repeat motifs as extracellular domains, and has, as intracellular domain, a TNF receptor-related factor (TRAF) binding sequence that stimulates NF κ B signal. CD197 and CD45RA 25 are used as marker molecules for distinguishing, in T cells, naive T cell or stem cell memory T cell (CD197-positive, CD45RA-positive), central memory T cell (CD197-positive, CD45RA-negative), effector memory T cell (CD197-negative, CD45RA-negative), and effector T cell (CD197-negative, CD45RA- 30 positive).

[0023]

In the production method or expansion culture method of the present invention, the CD3-positive cells to be cultured may be cells collected from a mammal or cells obtained by 35 differentiating pluripotent stem cells. Preferred are cells

obtained by differentiating pluripotent stem cells.

[0024]

When the CD3-positive cells are collected from a mammal, the cells can be isolated and collected, for example, by
5 collecting peripheral blood mononuclear cells (PBMC) from the mammal by apheresis, and then using anti-CD3 antibody column, density gradient centrifugation method and the like. Mammals for collecting CD3-positive cells include humans and animals other than human (e.g., dog, cat, mouse, rat, hamster, guinea
10 pig, rabbit, swine, bovine, goat, horse, sheep, monkey etc.), and human is preferable.

[0025]

When the CD3-positive cell is a cell obtained by differentiation of pluripotent stem cells, the pluripotent stem
15 cell include embryonic stem cell (ES cell), induced pluripotent stem cell (iPS cell), embryonal carcinoma cell (EC cell), and embryonic germ cell (EG cell). Preferred is ES cell or iPS cell (more preferred is human iPS cell).

[0026]

20 When the pluripotent stem cell is an ES cell, it can be produced by a method known per se. Examples of the production method of ES cell include, but are not limited to, a method of culturing an inner cell mass at the blastocyst stage of a mammal (see, for example, Manipulating the Mouse Embryo: A
25 Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1994)), and a method of culturing early embryo produced by somatic cell nuclear transfer (Wilmot et al., Nature, 385, 810(1997); Cibelli et al., Science, 280, 1256(1998); Akira Iriya et al., Protein Nucleic Acid Enzyme, 44, 892(1999); Baguisi et al., Nature Biotechnology, 17, 456(1999);
30 Wakayama et al., Nature, 394, 369(1998); Wakayama et al., Nature Genetics, 22, 127(1999); Wakayama et al., Proc. Natl. Acad. Sci. USA, 96, 14984(1999); RideoutIII et al., Nature Genetics, 24, 109(2000)) and the like. ES cells can be
35 obtained from a predetermined institution, and can also be

purchased as a commercial product. For example, human ES cell lines H1, H7, H9, H13 and H14 are available from WiCell Research Institute in the United States, human ES cell lines HES1 - 6 are available from ES Cell International in Australia, 5 human ES cell lines SA002, SA181 and SA611 are available from Cellartis AB in Sweden, human ES cell lines HUES1 - 17 are available from HUES Cell Facility in the United States, human ES cell lines KhES-1 - KhES-5 are available from the Institute for Frontier Life and Medical Sciences, Kyoto University, and 10 human ES cell lines SEES1 - SEES7 are available from the National Center for Child Health and Development. When ES cell is produced by somatic cell nuclear transfer, the type of somatic cells and the source for collecting somatic cells are the same as those in the production of iPS cells described 15 below.

[0027]

When the pluripotent stem cell is an iPS cell, the iPS cell can be produced by introducing a nuclear reprogramming substance into the somatic cell. The somatic cells that can be 20 used as a starting material for producing iPS cells may be any cell other than germ cells derived from mammals (e.g., mouse or human). Examples include keratinizing epithelial cells (e.g., keratinized epidermal cell), mucosal epithelial cells (e.g., epithelial cell on tongue surface layer), exocrine gland 25 epithelial cells (e.g., mammary cell), hormone secretory cells (e.g., adrenal medulla cell), metabolic/storage cells (e.g., hepatocyte), luminal epithelial cells that constitute the interface (e.g., type I alveolar cell), vascularluminal epithelial cells (e.g., vascular endothelial cell), ciliated 30 cells with transporting capacity (e.g., airway epithelial cell), extracellular matrix secretion cells (e.g., fibroblast), contractile cells (e.g., smooth muscle cell), blood and immune system cells (e.g., T lymphocyte), cells relating to sensor (e.g., rod cell), autonomic nervous system neurons (e.g., 35 cholinergic neuron), sensory organ and peripheral neuron-

supporting cells (e.g., satellite cell), nerve cells and glial cells of central nervous system (e.g., astroglial cell), pigment cells (e.g., retinal pigment epithelial cell), and progenitor cells thereof (tissue progenitor cell) and the like.

5 The degree of cell differentiation is not particularly limited, and both undifferentiated progenitor cells (including somatic stem cells) and finally-differentiated mature cells can be similarly used as the origin of the somatic cell in the present invention. As used herein, examples of the undifferentiated
10 progenitor cell include tissue stem cells (somatic stem cells) such as fat-derived stroma (stem) cell, neural stem cell, hematopoietic stem cell, mesenchymal stem cell, pulp stem cell and the like.

[0028]

15 Nuclear reprogramming substance to be introduced into somatic cells for the production of iPS cells includes combinations of various reprogramming genes reported so far (see, for example, WO 2007/069666, Nature Biotechnology, 26, 101-106 (2008), Cell, 126, 663-676 (2006), Cell, 131, 861-872
20 (2007), Nat. Cell Biol., 11, 197-203 (2009), Nature, 451, 141-146 (2008), Science, 318, 1917-1920 (2007), Stem Cells, 26, 1998-2005 (2008), Cell Research (2008) 600-603, Nature 454: 646-650 (2008), Cell Stem Cell, 2: 525-528(2008), WO2008/118820, Nat. Cell Biol., 11, 197-203 (2009), Nat. Cell Biol., 11, 197-
25 203 (2009), Science, 324: 797-801 (2009)). In addition, a protein encoded by the above-mentioned reprogramming gene can also be introduced as a nuclear reprogramming substance into a somatic cell (Cell Stem Cell, 4: 381-384(2009), Cell Stem Cell, doi:10.1016/j.stem.2009.05.005 (2009)). In particular, a
30 combination of the three factors Oct3/4, Sox2 and Klf4 is preferable, considering that the obtained iPS cells are used for therapeutic purposes.

[0029]

iPS cell colony can be selected by a method using drug
35 resistance and reporter activity as indices (Cell, 126, 663-676

(2006), Nature, 448, 313-317 (2007)) or a method including visual morphological observation (Cell, 131, 861-872 (2007)). Confirmation of iPS cell can be performed using the expression of various ES cell-specific genes and teratoma formation as
5 indices.

[0030]

Currently, there are various types of the iPS cell (iPSC), and iPS cell established by Yamanaka, et al. by introducing 4 factors of Oct3/4, Sox2, Klf4, c-Myc into mouse fibroblast
10 (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), iPSC derived from a human cell established by introducing similar 4 factors into human fibroblast (Takahashi K, Yamanaka S., et al., Cell, (2007) 131: 861-872.), Nanog-iPSc established by selecting with the expression of Nanog as an index after
15 introduction of the above-mentioned 4 factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317.), iPSC produced by a method free of c-Myc (Nakagawa M, Yamanaka S., et al., Nature Biotechnology, (2008) 26, 101 - 106), and iPSC established by introducing 6 factors by a virus-free
20 method (Okita K et al., Nat. Methods 2011 May; 8(5):409-12, Okita K et al., Stem Cells. 31(3):458-66.) can also be used. In addition, iPSC established by Thomson et al. by introducing 4 factors of OCT3/4, SOX2, NANOG, and LIN28 (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920.), iPSC produced by Daley
25 et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), induced pluripotent stem cell produced by et al. (JP-A-2008-307007) and the like can also be used.

In addition, any of the iPSCs known in the art that are described in published papers (e.g., Shi Y., Ding S., et al.,
30 Cell Stem Cell, (2008) Vol3, Issue 5, 568-574; Kim JB., Scholer HR., et al., Nature, (2008) 454, 646-650; Huangfu D., Melton, DA., et al., Nature Biotechnology, (2008) 26, No 7, 795-797), or patents (e.g., JP-A-2008-307007, JP-A-2008-283972, US2008-2336610, US2009-047263, WO2007/069666, WO2008/118220,
35 WO2008/124133, WO2008/151058, WO2009/006930, WO2009/006997,

WO2009/007852) can be used.

As the induced pluripotent stem cell line, various iPSC lines established by NIH, RIKEN, Kyoto University and the like can be used. Examples of the human iPSC line include HiPS-
5 RIKEN-1A strain, HiPS-RIKEN-2A strain, HiPS-RIKEN-12A strain, Nips-B2 strain of RIKEN, 253G1 strain, 253G4 strain, 1201C1 strain, 1205D1 strain, 1210B2 strain, 1383D2 strain, 1383D6 strain, 201B7 strain, 409B2 strain, 454E2 strain, 606A1 strain, 610B1 strain, 648A1 strain, 1231A31 strain, FfI-01s04 and the
10 like, and 1231A3 strain is preferable.
[0031]

When a CD3-positive cell is a cell obtained by differentiating a pluripotent stem cell, the TCR expressed in the CD3-positive cell includes a dimer consisting of two out of
15 TCR α , TCR β , TCR γ and TCR δ , a heterodimer consisting of TCR α and TCR β ($\alpha\beta$ TCR), a heterodimer consisting of TCR γ and TCR δ ($\gamma\delta$ TCR), and a homodimer consisting of the same TCR chain. While these TCRs may be endogenous dimers or exogenous dimers, a dimer containing exogenous TCR α and exogenous TCR β is preferable.

20 In the present specification, the "exogenous TCR" refers to a heterodimer consisting of an exogenous TCR α and an exogenous TCR β , a heterodimer consisting of an exogenous TCR γ and an exogenous TCR δ , and/or a homodimer consisting of the same exogenous TCR chain.

25 When TCR is a dimer containing endogenous TCR α and endogenous TCR β , the pluripotent stem cell may be a pluripotent stem cell prepared from a cell containing a nucleic acid containing a base sequence encoding endogenous TCR α and a nucleic acid containing a base sequence encoding endogenous
30 TCR β . Examples of such cell include T cells (CD8-positive CD4-negative cell, CD8-negative CD4-positive cell, CD4-positive CD8-positive cell and the like). When TCR is a dimer containing exogenous TCR α and exogenous TCR β , then the pluripotent stem cell may be a cell containing a nucleic acid
35 containing a base sequence encoding an exogenous TCR α and

nucleic acid containing a base sequence encoding an exogenous TCR β .

In the present specification, the "exogenous TCR nucleic acid" refers to a nucleic acid containing a base sequence
5 encoding an exogenous TCR α , nucleic acid containing a base sequence encoding an exogenous TCR β , nucleic acid containing a base sequence encoding an exogenous TCR γ , and/or a nucleic acid containing a base sequence encoding an exogenous TCR δ .

[0032]

10 The method for introducing an exogenous TCR nucleic acid (e.g., nucleic acid containing a base sequence encoding an exogenous TCR α and nucleic acid containing a base sequence encoding an exogenous TCR β) into a pluripotent stem cell is not particularly limited. For example, the following method can be
15 used.

[0033]

When the exogenous TCR nucleic acid is in the form of a DNA, for example, vectors such as virus, plasmid, artificial chromosome, and the like can be introduced into pluripotent
20 stem cells by methods such as lipofection, liposome, microinjection, and the like. Examples of the virus vector include retrovirus vector, lentivirus vector, adenovirus vector, adeno-associated virus vector, Sendai virus vector and the like. Examples of the artificial chromosome vector include human
25 artificial chromosome (HAC), yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC, PAC) and the like. As the plasmid, plasmid for mammalian cell can be used. The vector can contain control sequences such as promoter, enhancer, ribosome-binding sequence, terminator, polyadenylation sites
30 and the like so that exogenous TCR can be expressed. Where necessary, selection marker sequences such as drug resistance gene (e.g., kanamycin resistance gene, ampicillin resistance gene, puromycin resistance gene and the like), thymidine kinase gene, diphtheria toxin gene and the like, reporter gene
35 sequences such as fluorescent protein, β glucuronidase (GUS),

FLAG and the like, and the like can be contained. Examples of the promoter include SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney mouse leukemia virus) LTR, HSV-TK (herpes simplex virus thymidine kinase) promoter, EF- α promoter, CAG promoter and medicament responsive promoter. Examples of the drug responsive promoter include TRE promoter (CMV minimum promoter having a Tet-responsive sequence having 7 consecutive tetO sequences) that expresses a gene in the presence of the corresponding drug. When TRE promoter is used, it is preferable to use a mode that induces gene expression by simultaneously expressing a fusion protein of reverse tetR (rtetR) and VP16AD in the same cell in the presence of the corresponding drug (e.g., tetracycline or doxycycline). Further preferred is a vector having the TRE promoter and concurrently having a mode that expresses the fusion gene of rtetR and VP16AD in the same vector.

[0034]

In the present invention, a polycistronic expression mode may also be used to simultaneously express exogenous TCR α and exogenous TCR β . For polycistronic expression, the sequences encoding the genes may be linked by an IRES or foot-and-mouth disease virus (FMDV) 2A coding region.

[0035]

In another other embodiment, the above-mentioned vector may have a transposon sequence before and after this expression cassette (gene expression unit containing a promoter, a gene sequence and a terminator) to excise as necessary the sequence encoding the exogenous TCR incorporated into the chromosome. The transposon sequence is not particularly limited, and exemplified by piggyBac. In another embodiment, to remove the expression cassette, the loxP sequence or the FRT sequence may be provided before and after the expression cassette.

[0036]

When the exogenous TCR nucleic acid is in the form of an

RNA, it may be introduced into pluripotent stem cells by a method such as electroporation, lipofection, microinjection, and the like.

[0037]

5 In the production method or expansion culture method of the present invention, the CD3-positive cells to be cultured may also be cells expressing a chimeric antigen receptor.

[0038]

In the present invention, the "chimeric antigen receptor
10 (CAR)" means a fusion protein containing an antigen-binding domain, a transmembrane domain, and an intracellular signal transduction domain. The antigen-binding domain of CAR includes a short chain antibody (scFv) in which the light chain (VL) and heavy chain (VH) of the variable region of the
15 antibody are linked in tandem via a linker (e.g., GS linker). The CD3-positive cells expressing CAR recognize the antigen in the scFV region and then transduce the recognition signal thereof into T cells through the intracellular signal transduction domain. Introduction of CAR into the CD3-positive
20 cells makes it possible to impart specificity to the antigen of interest. In addition, since CAR can directly recognize antigen molecules without depending on HLA class I or class II, a high immune response can also be induced against cells with decreased HLA class I or class II gene expression.

25 [0039]

Examples of the antigen targeted by the above-mentioned TCR and CAR include, but are not limited to, tumor antigens. The tumor antigen may be a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). Specific examples of such
30 tumor antigen include one or more kinds of antigens selected from the group consisting of differentiated antigens such as MART-1/MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2 and the like, tumor-specific multilineage antigens such as WT1, Glypican-3, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15
35 and the like, fetal antigens such as CEA and the like,

overexpressed tumor genes or mutated tumor suppressive genes such as p53, Ras, HER-2/neu and the like, unique tumor antigens caused by chromosome translocation such as BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR and the like, and virus antigens such as Epstein Barr virus antigen EBVA, human papilloma virus (HPV) antigens E6 and E7 and the like. As other tumor antigens, CD19, CD20, EGP2, erB2,3,4, GD2, GD3, Mesothelin, PSMA, 8H9, Lewis-Y, MUC1, TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, β -catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, α -fetoprotein, β -HCG, BCA225, BTAA, CA 125, CA 15-3/CA 27.29/BCAA, CA 195, CA 242, CA-50, CAM43, CD68/P1, CO-029, FGF-5, G250, Ga733/EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90/Mac-2 binding protein/cyclophilin C-associated protein, TAAL6, TAG72, TLP and TPS can be mentioned.

[0040]

Examples of the transmembrane domain of CAR include a transmembrane domain derived from a protein selected from the group consisting of α chain, β chain or ζ chain of TCR, CD28, CD3 ϵ chain, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, 4-1BB (CD137) and CD154, and the like. Among these, a transmembrane domain derived from CD8 is preferable. In addition, for example, a transmembrane domain derived from a molecule, from which the first intracellular signal transduction domain linked to an antigen binding domain is derived, is also preferably used. When, for example, the molecule from which the first intracellular signal transduction domain linked to an antigen binding domain is derived is CD28, the transmembrane domain may also be derived from CD28. Alternatively, an artificially-designed transmembrane domain may also be used.

[0041]

Examples of the intracellular signal transduction domain of CAR include, but are not limited to, intracellular domains

derived from one or more kinds of proteins selected from the group consisting of FcR γ chain, FcR β chain, CD3 γ chain, CD3 δ chain, CD3 ϵ chain, CD3 ζ chain, CD5, CD22, CD79a, CD79b and CD66d. Among these, an intracellular domain derived from CD3 ζ chain is preferable. When tyrosine phosphorylation of ITAM contained in the intracellular domain of the CD3 ζ chain is triggered, a series of responses occur such as an increase in intracellular Ca²⁺ concentration, cytokine secretion, and the like, and finally, cell division occurs and CD3-positive cells show cytotoxic activity as CTL. The intracellular signal transduction domain may further contain an intracellular domain of a co-stimulating molecule. Examples of the co-stimulating molecule include, but are not limited to, intracellular domains of one or more kinds of proteins selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3 and CD83. Among these, intracellular domains derived from CD28, 4-1BB (CD137), CD30 are preferable. CD28 can bind to promote T cell proliferation by increasing IL-2 production. Also, 4-1BB can promote differentiation into memory cells by suppressing apoptosis caused in the final stage of T cell activation. CD30 can further improve the proliferation of CD3-positive cells with a CD3 antibody and makes it possible to maintain the cells as CD197-positive cells for a long term. By selecting the type and number of co-stimulating molecule, the strength and duration of CAR activity can be controlled (e.g., Mol Ther. 2009; 17:1453-1464). When the intracellular signal transduction domain contains one or more kinds of intracellular domains, the order thereof is not limited.

[0042]

A spacer may be incorporated between the antigen-binding domain of CAR and the transmembrane domain, or between the intracellular signal transduction domain of CAR and the transmembrane domain. As the spacer, a peptide consisting of

not more than 300 amino acids, preferably 10 to 100 amino acids, and most preferably 25 to 50 amino acids, can be generally used. Specific examples thereof include, but are not limited to, a hinge region derived from IgG1, a peptide containing a CH2CH3
5 region of immunoglobulin and a part of CD3, and the like.

[0043]

Specific examples of CAR include, but are not limited to, a first-generation CAR in which scFv and CD3 ζ chain are linked via a spacer, a second-generation CAR in which a transmembrane
10 domain and an intracellular domain derived from CD28 are incorporated between scFv of the first-generation CAR and the CD3 ζ chain to enhance the T cell activation ability, and a third generation CAR in which an intracellular domain of co-stimulating molecule (4-1BB or OX40) different from CD28 is
15 incorporated between the intracellular domain of CD28 of the second generation CAR and the CD3 ζ chain.

[0044]

In the production method or expansion culture method of the present invention, the CD3-positive cell to be cultured
20 further may be cells that co-express CAR and a fusion protein of IL-15 and IL-15R α (IL-15/IL-15R α). The CAR expressed with IL-15/IL-15R α may be similar to the above-mentioned CAR.

[0045]

In the present invention, the "IL-15/IL-15R α " means a
25 fusion protein containing IL-15 and IL-15R α . In the IL-15 signal transduction system, IL-15R α expressed on antigen-presenting cells generally binds to IL-15 and IL-15 is presented to IL-15 receptor consisting of a common γ chain (γ c) with IL-15R β on CD8-positive and CD4-negative cell (trans-
30 presentation), whereby the cytotoxic activity of CD8-positive CD4-negative cell is maintained. Therefore, when the CD3-positive cell expressing IL-15/IL-15R α is CD8-positive CD4-negative, the cell can transmit the IL-15 signal into its own cell via the IL-15 receptor. Alternatively, the CD3-positive
35 cell expressing IL-15/IL-15R α can transmit the IL-15 signal

into other CD8-positive CD4-negative cells via the IL-15 receptor. As described above, since IL-15/IL-15R α can maintain cytotoxic activity of CD8-positive CD4-negative cell, it is expected to show a continuous cytotoxic effect on cells
5 targeted by CAR.

[0046]

IL-15/IL-15R α may be a transmembrane type protein or a secretor protein. It is known that, in IL-15R α , the IL-15 binding domain of 1-65 amino acids from the N-terminal of the
10 mature protein is the region responsible for binding to IL-15 (Wei X. et al., J. Immunol., 167: 277-282, 2001). Therefore, the transmembrane type protein may be a protein that retains the IL-15 binding domain and retains the transmembrane domain of IL-15R α . On the other hand, the secretor protein may be a
15 protein that maintains the IL-15 binding domain and lacks the transmembrane domain of IL-15R α .

[0047]

A spacer may be incorporated between IL-15 and IL-15R α of IL-15/IL-15R α . As the spacer, a peptide generally
20 consisting of not more than 300 amino acids, preferably 10 - 100 amino acids, most preferably 20 - 50 amino acids, can be used. Specific examples thereof include, but are not limited to, GS linker and the like.

[0048]

25 IL-15/IL-15R α is not particularly limited as long as it is a peptide in which IL-15 and IL-15R α are bonded via a spacer, and specific examples thereof include a peptide consisting of SEQ ID NO: 8. While IL-15/IL-15R is not particularly limited as long as it can bind to the IL-15
30 receptor and transmit the IL-15 signal into the cell, for example, a peptide containing an amino acid sequence having a homology of not less than about 90%, preferably not less than about 95%, more preferably not less than about 97%, particularly preferably not less than about 98%, most
35 preferably not less than about 99%, with the amino acid

sequence shown in SEQ ID NO: 8 can be mentioned. As used herein, the "homology" means the proportion (%) of the same amino acid and similar amino acid residue to all overlapping amino acid residues in the optimal alignment where two amino acid sequences are aligned using a mathematic algorithm known in the relevant technical field (preferably, the algorithm is such that a gap can be introduced into one or both of the sequences for the optimal alignment). The "similar amino acid" means amino acids having similar physicochemical properties and, for example, amino acids classified in the same group such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Ala, Leu, Ile, Val), polar amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids having a hydroxyl group (Ser, Thr), amino acids having a small side chain (Gly, Ala, Ser, Thr, Met) and the like can be mentioned. It is predicted that the substitution with such similar amino acids does not change the phenotype of the protein (that is, conservative amino acid substitution). Specific examples of the conservative amino acid substitution are well known in the technical field and are described in various documents (e.g., Bowie et al., Science, 247: 1306-1310 (1990)). The homology of the amino acid sequence in the present specification can be calculated using homology calculation algorithm NCBI BLAST (National Center for Biotechnology Information Basic Local Alignment Search Tool), and under the following conditions (expectancy =10; accept gap; matrix =BLOSUM62; filtering =OFF).

[0049]

When chimeric antigen receptor and/or IL-15/IL-15R α are/is expressed in the CD3-positive cell cultured in the production method or expansion culture method of the present invention, a method for introducing the CAR nucleic acid and/or IL-15/IL-15R α nucleic acid into the cells (e.g., pluripotent stem cell) is not particularly limited and, for example, the same method as the method of introducing TCR nucleic acid can

be used.

[0050]

When the CD3-positive cell to be cultured in the production method or expansion culture method of the present invention are cells obtained by differentiating pluripotent stem cells, the pluripotent stem cells can be differentiated into CD3-positive cells by a method known per se. Specific methods for differentiating pluripotent stem cells into CD3-positive cells are described, for example, in WO 2016/076415 and WO 2017/221975. A specific method for differentiating pluripotent stem cells into CD3-positive cells may include, for example, (1) a process for differentiating pluripotent stem cells into hematopoietic progenitor cells, and (2) a process for differentiating the hematopoietic progenitor cells into CD3-positive cells.

[0051]

(1) Process for differentiating induced pluripotent stem cells into hematopoietic progenitor cells

In step (1), the hematopoietic progenitor cell (HPC) means CD34-positive cell, preferably, CD34positive CD43-positive (DP) cell. In the step (1), hematopoietic progenitor cell and hematopoietic stem cell are not distinguished and show the same cell unless particularly indicated.

[0052]

The method of differentiating pluripotent stem cells into hematopoietic progenitor cells is not particularly limited as long as it can cause differentiation into hematopoietic progenitor cells. Examples thereof include a method including culturing pluripotent stem cells in a medium for induction of hematopoietic progenitor cells, as described in, for example, WO 2013/075222, WO 2016/076415 and Liu S. et al., Cytotherapy, 17 (2015); 344-358 and the like.

[0053]

In step (1), a medium used for induction into hematopoietic progenitor cells is not particularly limited. A

medium used for culturing animal cells can be prepared into a basal medium. Examples of the basal medium include, but are not limited to, Dulbecco's Medium (e.g., IMDM), Eagle's medium (e.g., DMEM, EMEM, BME, MEM, α MEM), Ham's medium (e.g., F10 medium, F12 medium), RPMI medium (e.g., RPMI-1640 medium, RPMI-1630 medium), MCDB medium (e.g., MCDB104, 107, 131, 151, 153 medium), Fischer's medium, 199 medium, culture medium for primate ES cell (culture medium for primate ES/iPS cell, Reprocell), medium for mouse ES cell (TX-WES culture medium, Thromb-X), serum-free medium (mTeSR, Stemcell Technologies), ReproFF, StemSpan (registered trade mark) SFEM, StemSpan (registered trade mark) H3000, StemlineII, ESF-B medium, ESF-C medium, CSTI-7 medium, Neurobasal medium (Life Technologies, Inc.), StemPro-34 medium, StemFit (registered trade mark) (e.g., StemFit AK03N, StemFit AK02N) and the like. Furthermore, these media can be mixed as necessary and used and, for example, DMEM/F12 medium and the like can be mentioned. The basal medium used may contain a serum, or may be serum-free. The basal medium may be appropriately supplemented with 10 - 20% serum (fetal bovine serum (FBS), human serum, horse serum) or a serum replacement (KSR and the like), insulin, various vitamins, L-glutamine, various amino acids such as non-essential amino acid and the like, 2-mercaptoethanol, various cytokines (interleukins (IL-2, IL-7, IL-15 etc.), SCF (Stem cell factor), activin and the like), various hormones, various growth factors (Leukemia inhibitory factor (LIF), basic fibroblast growth factor (bFGF), TGF- β etc.), various extracellular matrices, various cell adhesion molecules, antibiotics such as penicillin/streptomycin, puromycin and the like, pH indicator such as phenol red and the like, and the like. If necessary, the basal medium may also contain Vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compound (e.g., sodium selenite), fatty acid, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α -monothioglycerol (MTG)), lipids, L-alanyl-L-glutamine (e.g., Glutamax (registered trade mark)),

growth factors, low-molecular-weight compounds, antibiotics, antioxidants, pyruvic acid, buffers, inorganic salts, and the like.

[0054]

5 In step (1), "Vitamin C" means L-ascorbic acid and derivatives thereof, and "L-ascorbic acid derivative" means derivatives that become vitamin C by enzymatic reaction in the living body. Examples of the derivatives of L-ascorbic acid used in step (1) include vitamin C phosphate, ascorbic acid
10 glucoside, ascorbyl ethyl, vitamin C ester, ascorbyl tetrahexyldecanoate, ascorbyl stearate, and ascorbyl 2-phosphate 6-palmitate. Preferred is vitamin C phosphate. Examples of the vitamin C phosphate (e.g., ascorbic acid 2-phosphate) include salts of L-ascorbic acid phosphate such as
15 L-ascorbic acid phosphate Na and L-ascorbic acid phosphate Mg.
[0055]

When Vitamin C is used, the Vitamin C is preferably added (supplied) every four days, every three days, every two days, or every day. Vitamin C is more preferably added every day.
20 In one embodiment, Vitamin C is preferably added to the medium at an amount corresponding to 5 ng/ml to 500 ng/ml (e.g., an amount corresponding to 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, or 500 ng/ml). In another embodiment, Vitamin C is added to the culture medium at
25 an amount corresponding to 5 µg/ml - 500 µg/ml (e.g., an amount corresponding to 5 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, 200 µg/ml, 300 µg/ml, 400 µg/ml, 500 µg/ml).
[0056]

The medium to be used in step (1) may be further
30 supplemented with at least one kind of cytokine selected from the group consisting of BMP4 (Bone morphogenetic protein 4), VEGF (vascular endothelial growth factor), SCF (Stem cell factor), TPO (thrombopoietin), FLT-3L (Flt3 Ligand) and bFGF (basic fibroblast growth factor). It is more preferably a
35 culture supplemented with BMP4, VEGF and bFGF, and further

preferably a culture supplemented with BMP4, VEGF, SCF and bFGF.
[0057]

When cytokine is used, its concentration in the medium may be, for example, 5 ng/ml - 500 ng/ml for BMP4, 5 ng/ml -
5 500 ng/ml for VEGF, 5 ng/ml - 500 ng/ml for SCF, 3 ng/ml - 300
ng/ml for TPO, 1 ng/ml - 100 ng/ml for FLT-3L, and 5 ng/ml -
500 ng/ml for bFGF.
[0058]

The medium may be supplemented with a TGF β inhibitor.
10 The TGF β inhibitor is a small molecule inhibitor that
interferes with the signal transduction of TGF β family and
includes, for example, SB431542, SB202190 (both R.K. Lindemann
et al., Mol. Cancer 2:20 (2003)), SB505124 (GlaxoSmithKline),
NPC30345, SD093, SD908, SD208 (Scios), LY2109761, LY364947,
15 LY580276 (Lilly Research Laboratories) and the like. For
example, when the TGF β inhibitor is SB431542, its concentration
in the medium is preferably 0.5 μ M - 100 μ M.
[0059]

The induced pluripotent stem cells may be cultured by
20 adherent culture or suspension culture. In cases of adherent
culture, the culturing may be carried out in a culture vessel
coated with an extracellular matrix component, and/or may be
co-cultured with feeder cells. While the feeder cell is not
particularly limited, for example, fibroblast (mouse embryo
25 fibroblast (MEF), mouse fibroblast (STO) and the like) can be
mentioned. Feeder cells are preferably inactivated by a method
known per se, for example, radiation (gamma-ray and the like)
irradiation, treatment with anti-cancer agent (mitomycin C and
the like) and the like. As the extracellular matrix component,
30 fibrous proteins such as Matrigel (Niwa A, et al., PLoS
One.6(7): e22261, 2011), gelatin, collagen, elastin and the
like, glucosaminoglycan and proteoglycan such as hyaluronic
acid, chondroitin sulfate and the like, cell adhesion proteins
such as fibronectin, vitronectin, laminin and the like, and the
35 like can be mentioned.

[0060]

Suspension culture means culturing cells in a state of non-adhesion to a culture container and is not particularly limited. To improve adhesiveness to the cells, a culture container free of an artificial treatment (e.g., coating treatment with extracellular matrix and the like), or a culture container subjected to a treatment for artificially suppressing adhesion (e.g., coating treatment with polyhydroxyethyl methacrylic acid (poly-HEMA) or non-ionic surface-active polyol (Pluronic F-127 etc.)) can be used. In the suspension culture, embryoid (EB) is preferably formed and cultured.

[0061]

Hematopoietic progenitor cell can also be prepared from a sac-like structure (to be also referred to as ES-sac or iPS-sac) obtained by culturing pluripotent stem cells. As used herein, the "sac-like structure" is a pluripotent stem cell-derived three-dimensional saccular (with spaces inside) structure, which is formed by an endothelial cell population and the like and contains hematopoietic progenitor cells in the inside thereof.

[0062]

The temperature conditions in step (1) are not particularly limited. The temperature is, for example, about 37°C to about 42°C, preferably about 37°C to about 39°C. The culture period may be appropriately determined by those skilled in the art by monitoring of the number of hematopoietic progenitor cells and/or the like. The number of days of the culture is not limited as long as hematopoietic progenitor cells can be obtained. Examples of the culture period include at least 6 days, not less than 7 days, not less than 8 days, not less than 9 days, not less than 10 days, not less than 11 days, not less than 12 days, not less than 13 days, and not less than 14 days. The culture period is preferably 14 days. While a longer culture period generally does not pose a problem in the production of hematopoietic progenitor cells, it is

preferably not more than 35 days, more preferably not more than 21 days. The culture may be carried out under low-oxygen conditions, and the low-oxygen condition in the present specification means, for example, oxygen concentration of 15%,
5 10%, 9%, 8%, 7%, 6%, 5% or lower than these.

[0063]

(2) Step of differentiating hematopoietic progenitor cells into CD3-positive cells

A method for differentiating hematopoietic progenitor
10 cells into CD3-positive cells is not particularly limited as long as it can differentiate hematopoietic progenitor cells into CD3-positive cells. Examples thereof include a method for culturing hematopoietic progenitor cells under the same culture conditions as those in a method of inducing T cells from
15 hematopoietic progenitor cells, as described in WO 2016/076415, WO 2017/221975 and the like.

[0064]

In step (2), a medium for inducing differentiation into CD3-positive T cell is not particularly limited, and a medium
20 used for culturing animal cells can be prepared into a basal medium. Examples of the basal medium include those similar to the basal medium used in the above-mentioned step (1). The medium may contain serum, or may be serum-free. If necessary, the basal medium may also contain Vitamin C (e.g., ascorbic
25 acid), albumin, insulin, transferrin, selenium compound (e.g., sodium selenite), fatty acid, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α -monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trade mark)), non-essential amino acids, vitamins,
30 growth factors, low-molecular-weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, and the like.

[0065]

When vitamin C is used in step (2), Vitamin C may be the
35 same as that described in step (2-1) and can be added similarly.

In one embodiment, the concentration of vitamin C in the medium or culture medium is preferably 5 µg/ml - 200 µg/ml. In another embodiment, vitamin C is added to the culture medium at an amount corresponding to 5 µg/ml - 500 µg/ml (e.g., amount
5 corresponding to 5 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml, 200 µg/ml, 300 µg/ml, 400 µg/ml, 500 µg/ml).

[0066]

In step (2), p38 inhibitor and/or SDF-1 (Stromal cell-derived factor 1) are/is preferable. In the present
10 specification, the "p38 inhibitor" means a substance that inhibits the functions of p38 protein (p38 MAP kinase). Examples thereof include, but are not limited to, chemical inhibitor of p38, dominant-negative mutant of p38 or nucleic acid encoding same and the like.

15 [0067]

Examples of the chemical inhibitor of p38 to be used in step (2) include, but are not limited to, SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole), and a derivative thereof, SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole)
20 and a derivative thereof, SB239063 (trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]cyclohexanol) and a derivative thereof, SB220025 and a derivative thereof, PD169316, RPR200765A, AMG-548, BIRB-796,
25 SC10-469, SC10-323, VX-702 and FR167653. These compounds are commercially available and, for example, SB203580, SB202190, SB239063, SB220025 and PD169316 are available from Calbiochem, and SC10-469 and SC10-323 are available from Scios and the like. The chemical inhibitor of p38 is preferably SB203580 (4-(4-
30 fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole), or a derivative thereof.

[0068]

Examples of the dominant-negative mutant of p38 in step (2) include p38T180A obtained by point mutation of the 180-
35 position threonine located in the DNA binding region of p38 to

alanine, p38Y182F obtained by point mutation of the 182-position tyrosine of p38 in human and mouse to phenylalanine and the like. The p38 inhibitor is contained in a medium at, for example, about 1 μ M - about 50 μ M. When SB203580 is used
5 as the P38 inhibitor, it may be contained in a medium at 1 μ M - 50 μ M, 5 μ M - 30 μ M, 10 μ M - 20 μ M.

[0069]

SDF-1 in step (2) may be not only SDF-1 α or a mature form thereof, but also an isoform such as SDF-1 β , SDF-1 γ , SDF-
10 1 δ , SDF-1 ϵ , SDF-1 ϕ and the like or a mature form thereof, or a mixture of these at any ratio or the like. Preferably, SDF-1 α is used. SDF-1 is sometimes referred to as CXCL-12 or PBSF.

[0070]

In step (2), one or several amino acids in the amino acid
15 sequence of SDF-1 may be substituted, deleted, added and/or inserted as long as it has the activity as the chemokine (SDF-1 with such substitution, deletion, addition and/or insertion of amino acid is to be also referred to as "SDF-1 mutant"). Similarly, sugar chain may be substituted, deleted and/or added
20 in SDF-1 or SDF-1 mutant. Examples of the mutant of the above-mentioned SDF-1 include those maintaining at least 4 cysteine residues (Cys30, Cys32, Cys55 and Cys71 in human SDF-1 α) and having not less than 90% identity with amino acid sequence of a natural substance, though the amino acid mutation is not
25 limited thereto. SDF-1 may be obtained from a mammal, for example, human or non-human mammal such as monkey, sheep, bovine, horse, swine, dog, cat, rabbit, rat, mouse and the like. For example, the protein registered as GenBank accession number:NP_954637 can be used as human SDF-1 α , and the protein
30 registered as GenBank accession number:NP_000600 can be used as SDF-1 β .

[0071]

SDF-1 may be commercially available, purified from nature, or produced by peptide synthesis or genetic engineering
35 techniques. SDF-1 is contained in a medium within the range of,

for example, about 10 ng/ml to about 100 ng/ml. In addition, SDF-1 alternative having an SDF-1-like activity can also be used instead of SDF-1. Examples of such SDF-1 alternative include CXCR4 agonist, and a low-molecular-weight compound
5 having a CXCR4 agonist activity and the like may be added to the medium instead of SDF-1.

[0072]

The culture medium used in step (2) may be further supplemented with at least one kind, preferably all, of
10 cytokine selected from the group consisting of SCF, TPO (thrombopoietin), FLT-3L and IL-7. The concentration of these is, for example, 10 ng/ml to 100 ng/ml for SCF, 10 ng/ml to 200 ng/ml for TPO, 1 ng/ml to 100 ng/ml for IL-7, and 1 ng/ml to 100 ng/ml for FLT-3L.

15 [0073]

In step (2), the hematopoietic progenitor cells may be cultured by adherent culture or suspension culture. In cases of adherent culture, a coated culture vessel may be used, and/or the hematopoietic progenitor cells may be co-cultured
20 with feeder cells and/or the like. Examples of the feeder cells for the co-culture include a bone-marrow stromal cell line, OP9 cells (available from Riken BioResource Center). The OP9 cell is preferably OP9-DL4 cell or OP9-DL1 cell, which constantly expresses DLL4 or DLL1 (e.g., Holmes R I and Zuniga-
25 Pflucker J C. Cold Spring Harb Protoc. 2009(2)). In step (2), in cases where OP9 cells are used as the feeder cells, DLL1, or a separately-prepared DLL4 or DLL1, or a fusion protein of DLL4 or DLL1, and Fc or the like, may be added to the medium to perform the co-culture. When feeder cells are used, the feeder
30 cells are preferably appropriately replaced during the culture. The replacement of the feeder cells may be carried out by transferring the subject cells that are being cultured onto feeder cells that are preliminarily plated. The replacement may be carried out every five days, every four days, every
35 three days, or every two days. When hematopoietic progenitor

cells are obtained by suspension culture of embryoid, it is preferable to perform adhesion culture after dissociation into single cells. While the cells may be co-cultured with feeder cells, culturing is preferably carried out without using feeder
5 cells.

In the case of adhesion culture and when a culture container is coated, examples of the coating agent include Matrigel (Niwa A, et al. Plos One, 6(7):e22261, 2011)), collagen, gelatin, laminin, heparan sulfuric acid proteoglycan,
10 RetroNectin, fusion protein of DLL4 or DLL1, or DLL4 or DLL1, and Fc region of antibody (hereinafter sometimes referred to as Fc) and the like (e.g., DLL4/Fc chimera), entactin, and/or combination of these, and a combination of RetroNectin and fusion protein of DLL4 and Fc etc. is preferable.

15 [0074]

In step (2), the culture temperature conditions are not limited. The temperature is, for example, about 37°C to about 42°C, preferably about 37 to about 39°C. The culture period may be appropriately determined by those skilled in the art by
20 monitoring of the number of CD3-positive cells and the like. The number of days of the culture is not limited as long as CD3-positive cells can be obtained. Examples of the culture period include at least not less than 10 days, not less than 12 days, not less than 14 days, not less than 16 days, not less
25 than 18 days, not less than 20 days, not less than 22 days, and not less than 23 days. The culture period is preferably 21 days. In addition, not more than 90 days is preferable, and not more than 42 days is more preferable.

[0075]

30 The cells obtained by the above steps include CD3-positive cells. A specific method for differentiating pluripotent stem cells into CD3-positive cells may further include the following step (3).

[0076]

35 (3) Step of obtaining CD3-positive CD8-positive CD4-negative

cell (or CD3-positive CD8-positive CD4-negative CD30-positive cell) or step of enriching CD3-positive cell

Examples of the method for obtaining CD3-positive CD8-positive CD4-negative cell (or CD3-positive CD8-positive CD4-negative CD30-positive cell) include the methods described in WO 2016/076415, WO 2017/221975 and the like. CD3-positive cell may also be enriched using a similar method.

[0077]

In step (3), a medium used for obtaining CD3-positive CD8-positive CD4-negative cell (or CD3-positive CD8-positive CD4-negative CD30-positive cell) or enriching CD3-positive cell is not particularly limited, and a medium used for culturing animal cells can be prepared into a basal medium. Examples of the basal medium include those similar to the basal medium used in the above-mentioned step (1). The medium may contain serum, or may be serum-free. If necessary, the basal medium may also contain Vitamin C (e.g., ascorbic acid), albumin, insulin, transferrin, selenium compound (e.g., sodium selenite), fatty acid, trace elements, 2-mercaptoethanol, thioglycerol (e.g., α -monothioglycerol (MTG)), lipids, amino acids, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trade mark)), non-essential amino acids, vitamins, growth factors, low-molecular-weight compounds, antibiotics (e.g., penicillin, streptomycin), antioxidants, pyruvic acid, buffers, inorganic salts, cytokines, hormone, and the like.

[0078]

When Vitamin C is used in step (3), Vitamin C may be similar to those described in step (1) and can be added similarly. In one embodiment, the concentration of Vitamin C in the medium or culture medium is preferably 5 $\mu\text{g/ml}$ - 200 $\mu\text{g/ml}$. In another embodiment, vitamin C is added in an amount corresponding to 5 $\mu\text{g/ml}$ - 500 $\mu\text{g/ml}$ in the culture medium (e.g., amount corresponding to 5 $\mu\text{g/ml}$, 10 $\mu\text{g/ml}$, 25 $\mu\text{g/ml}$, 50 $\mu\text{g/ml}$, 100 $\mu\text{g/ml}$, 200 $\mu\text{g/ml}$, 300 $\mu\text{g/ml}$, 400 $\mu\text{g/ml}$, 500 $\mu\text{g/ml}$).

[0079]

When hormone is used in step (3), examples of the hormone include corticosteroid. Corticosteroid is glucocorticoid or a derivative thereof, and cortisone acetate, hydrocortisone, fludrocortisone acetate, predonisolone, triamcinolone, methylprednisolone, dexamethasone, betamethasone, and beclometasone dipropionate are recited as examples. Preferred is dexamethasone. When corticosteroid is dexamethasone, its concentration in the medium is 1 nM - 100 nM.

[0080]

10 In step (3), the medium contains a CD3/TCR complex agonist. The CD3/TCR complex agonist is not particularly limited as long as it is a molecule capable of transducing a signal from a CD3/TCR complex to a CD3-positive cell by specifically binding to at least a part of the CD3/TCR complex.

15 Examples of the CD3/TCR complex agonist include CD3 agonist and/or TCR agonist. As the CD3 agonist, an anti-CD3 agonist antibody or a binding fragment thereof can be mentioned, and as the TCR agonist, at least one selected from the group consisting of an anti-TCR agonist antibody or a binding

20 fragment thereof, an MHC/antigen peptide complex or a multimer thereof, and an MHC/superantigen complex or a multimer thereof can be mentioned. When an anti-CD3 agonist antibody is used, the anti-CD3 agonist antibody includes both a polyclonal antibody and a monoclonal antibody, preferably a monoclonal

25 antibody. The antibody may belong to any immunoglobulin class of IgG, IgA, IgM, IgD and IgE, preferably IgG. As the anti-CD3 agonist antibody, an antibody (OKT3) produced from OKT3 clone, an antibody (UCHT1) produced from UCHT1 clone and the like can be mentioned, and it is preferably UCHT1. When the anti-CD3

30 agonist antibody is OKT3, OKT3 includes RYTMH (SEQ ID NO: 9), YINPSRGYTNYNQKFKD (SEQ ID NO: 10), and YYDDHYCLDY (SEQ ID NO: 11) as complementarity determining regions 1 - 3 in the heavy chain variable region, and SASSSVSYMN (SEQ ID NO: 12), DTSKLAS (SEQ ID NO: 13), and QQWSSNPFT (SEQ ID NO: 14) as

35 complementarity determining regions 1 - 3 in the light chain

variable region. In addition, OKT3 preferably includes a heavy chain variable region containing the amino acid sequence shown in SEQ ID NO: 21 and a light chain variable region containing the amino acid sequence shown in SEQ ID NO: 22. When the anti-
5 CD3 agonist antibody is UCHT1, UCHT1 includes GYSFTGYTMN (SEQ ID NO: 15), LINPYKGVST (SEQ ID NO: 16), and SGYYGDSDWYFDV (SEQ ID NO: 17) as complementarity determining regions 1 - 3 in the heavy chain variable region, and RASQDIRNYLN (SEQ ID NO: 18), YTSRLHS (SEQ ID NO: 19), and QQGNTLPWT (SEQ ID NO: 20) as
10 complementarity determining regions 1 - 3 in the light chain variable region. In addition, UCHT1 preferably includes a heavy chain variable region containing the amino acid sequence shown in SEQ ID NO: 23 and a light chain variable region containing the amino acid sequence shown in SEQ ID NO: 24. The
15 concentration of anti-CD3 agonist antibody in the medium is, for example, 10 ng/ml - 1000 ng/ml, preferably 50 ng/ml - 800 ng/ml, more preferably 250 ng/ml - 600 ng/ml.

[0081]

When cytokine is used in step (3), IL-2 and IL-7 and the
20 like can be mentioned as the cytokine. When cytokine is IL-2, the concentration thereof in the medium is 10 U/ml - 1000 U/mL, and when it is IL-7, the concentration thereof in the medium is 1 ng/ml - 1000 ng/mL.

[0082]

25 In step (3), the culture temperature conditions are not particularly limited. The temperature is, for example, about 37°C to about 42°C, preferably about 37°C to about 39°C. The culture period may be appropriately determined by those skilled in the art by monitoring of the number of CD3-positive cells
30 and the like. The number of days of the culture is not limited as long as CD3-positive cell cells can be obtained. The culture period is, for example, at least 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, and preferably 6 days. It is preferably 28 days or less, more
35 preferably 14 days or less.

[0083]

As described above, by differentiating pluripotent stem cells, CD3-positive cells to be cultured by the production method or expansion culture method of the present invention can
5 be obtained.

[0084]

The production method or expansion culture method of the present invention includes a step of culturing CD3-positive cells in the presence of a CD3/TCR complex agonist, fibronectin
10 or a variant thereof, and a CD30 agonist (hereinafter to be referred to as step (I) of the present invention).

[0085]

In step (I) of the present invention, the CD3/TCR complex agonist may be the same as the CD3/TCR complex agonist used in
15 the step (3).

[0086]

In step (I) of the present invention (or the step (3)), when the CD3/TCR complex agonist to be used is an anti-CD3 agonist antibody or an anti-TCR antibody, the polyclonal
20 antibodies thereof can be produced, for example, by the following method. For example, in the case of polyclonal antibody to CD3, mammals such as rabbit, mouse, rat, goat, guinea pig, hamster and the like are immunized (1 to several boosters every about 1 - 4 weeks from the initial immunization)
25 with a mixture of a partial peptide (e.g., γ , δ , ϵ , ζ chain) containing CD3 or an epitope thereof and complete or incomplete Freund's adjuvant (FCA or FIA) as an immunization antigen, and in the case of polyclonal antibody to TCR, the mammals are immunized with a mixture of a partial peptide (e.g., α , β , $\gamma\delta$
30 chain) containing TCR or an epitope thereof and complete or incomplete Freund's adjuvant (FCA or FIA) as an immunization antigen. About 3 to 10 days after each additional immunization, the antibody titer of the partially collected serum is measured using a conventionally known antigen-antibody reaction, and its
35 increase is confirmed. In addition, about 3-10 days after

final immunization, whole blood is collected and antiserum is purified. The polyclonal antibody can also be purified as a single immunoglobulin class by using a conventional separation technique such as salting out (e.g., ammonium sulfate
5 fractionation), centrifugation, dialysis, and column chromatography.

[0087]

When the anti-CD3 agonist antibody or anti-TCR antibody used in step (I) of the present invention (or the step (3)) is
10 a monoclonal antibody, the monoclonal antibody can be generally obtained from hybridomas (fusion cells) produced by cell fusion. That is, as in the above-mentioned polyclonal antibody, it can be produced by isolating antibody-producing cells from a mammal immunosensitized to a partial peptide containing CD3 or TCR or
15 an epitope thereof, fusing same with myeloma cells to form hybridoma, cloning the hybridoma, and selecting, as a marker antigen, a clone that produces an antibody that shows specific affinity for CD3 or TCR. In addition, an antibody-producing cell produced by reacting CD3 with splenocytes or lymphocytes
20 isolated in advance in a culture medium can also be used. In this case, human-derived antibody-producing cells can also be prepared.

[0088]

Hybridoma that secretes monoclonal antibody can be
25 prepared according to the method of Kohler and Milstein (Nature, Vol. 256, pp. 495-497, 1975) or a modified method thereof. That is, monoclonal antibody is prepared by culturing hybridoma obtained by fusing antibody-producing cells contained in splenocytes, thymocytes, lymph node cells, peripheral
30 lymphocytes, myeloma cells or tonsillaria, preferably splenocytes, obtained from animals immunosensitized as described above, with preferably myeloma cells of allogenic mammals such as mouse, rat, guinea pig, hamster, rabbit or human, more preferably mouse, rat or human. Culture can be
35 performed in vitro or in vivo in mammals such as mouse, rat,

guinea pig, hamster, rabbit, preferably mouse or rat, more preferably intraperitoneally in mice, and the antibody can be obtained from the culture supernatant or ascites of mammal.

[0089]

5 Examples of the myeloma cell used for cell fusion include mouse-derived myeloma (e.g., P3-NSI-1-Ag4-1, P3-X63-Ag8-U1, P3-X63-Ag8-653, SP2/0-Ag14, BW5147 and the like), rat-derived myeloma (e.g., 210RCY3-Ag1.2.3 and the like), human-derived myeloma (e.g., U-266AR1, GML500-6TG-A1-2, UC729-6, CEM-AGR,
10 D1R11 and CEM-T15 and the like) and the like.

[0090]

 A hybridoma clone that produces the monoclonal antibody can be screened for by culturing hybridoma in, for example, a micro titer plate, and measuring the reactivity of the culture
15 supernatant in the well, which showed proliferation, to CD3 by radioimmunoassay, enzyme immunoassay, fluorescence immunoassay and the like.

[0091]

 The isolation and purification of the monoclonal antibody
20 can be performed by subjecting the antibody-containing culture supernatant or ascites produced by the method described above to ion exchange chromatography, affinity column chromatography such as an anti-immunoglobulin column or protein G column.

[0092]

25 The monoclonal antibody used in step (I) of the present invention (or the step (3)) of the present invention is not may be obtained by any method without limited to the production method. While a monoclonal antibody generally has a sugar chain having a different structure according to the kind of
30 mammal to be immunosensitized, the monoclonal antibody in the present invention is not limited by the structural difference of the sugar chain and includes monoclonal antibodies derived from any mammals.

[0093]

35 The anti-CD3 agonist antibody or anti-TCR antibody

includes the polyclonal antibody, natural antibody such as monoclonal antibody (mAb), chimeric antibody (humanized antibody) that can be produced using gene recombination technology, single strand antibody, and binding fragments of
5 these antibodies. The binding fragment of an antibody means a region of a part of the antibody having specific binding activity, and specifically includes Fab, Fab', F(ab')₂, scAb, scFv, scFv-Fc, and the like.

[0094]

10 In addition, those skilled in the art can produce a fusion antibody of an anti-CD3 agonist antibody or an anti-TCR antibody or a binding fragment thereof with other peptide or protein, or a modified antibody to which a modifying agent is bound. Other peptides and proteins used for fusion are not
15 particularly limited as long as they do not reduce the binding activity of the antibody. For example, human serum albumin, various tag peptides, artificial helix motif peptides, maltose binding proteins, glutathione S transferase, various toxins, other peptides or proteins that can promote multimerization,
20 and the like can be mentioned. The modifying agent used for the modification is not particularly limited as long as it does not reduce the binding activity of the antibody, and examples thereof include polyethylene glycol, sugar chain, phospholipid, liposome, low-molecular-weight compound and the like.

25 [0095]

As the anti-CD3 agonist antibody, a reagent that can be purchased can also be used. The anti-CD3 agonist antibody that can be purchased is not particularly limited, and, for example, an antibody (OKT3) produced from an OKT3 clone (anti-human CD3
30 functional grade purified (Clone: OKT3) (eBioscience)), an antibody (UCHT1) produced from UCHT1 clone (CD3 antibody (Clone: UCHT1) (GeneTex)), and the like can be used, and UCHT1 can be preferably used.

[0096]

35 When the CD3/TCR complex agonist used in step (I) of the

present invention (or the step (3)) is an MHC/antigen peptide complex, the MHC/antigen peptide complex is not particularly limited as long as it is a molecule specifically recognized by CD3/TCR complex of CD3-positive cells and the molecule can
5 transmit a signal into CD3-positive cells.

[0097]

The MHC constituting the MHC/antigen peptide complex may be MHC class I or MHC class II, preferably MHC class I.

[0098]

10 In step (I) of the present invention (or the step (3)), MHC class I is not particularly limited as long as it is a molecule that forms a complex with an antigen peptide, is recognized by the CD3/TCR complex and CD8, and transmits a signal into CD3-positive cells. MHC class I is, for example, a
15 dimer composed α chain (HLA-A, HLA-B, HLA-C, HLA-E, HLA-F or HLA-G for human, H-2K, H-2D or H-2L for mouse) and β_2 microglobulin, preferably, a dimer composed of HLA-A, HLA-B, HLA-C, HLA-E, HLA-F or HLA-G, and β_2 microglobulin, more preferably, a dimer composed of HLA-A, HLA-B or HLA-C, and β_2
20 microglobulin. In the production method or the expansion culture method of the present invention, specific examples of the MHC class I include, but are not limited to, HLA-A*02:01, HLA-A*24:02, HLA-A*01:01, and the like. The antigen peptide is not particularly limited as long as it is a peptide presented
25 by MHC class I. As the antigen peptide presented by MHC class I, for example, HER-2/neu, MART-1, NY-ESO-1, Gp-100, MUC-1, p53, prostate-specific antigen (PSA), hTERT, WT1, survivin, CEA, MAGE-3, peptide derived from protein derived from a group of viruses strongly related to the development of malignant tumor,
30 and the like can be mentioned, and WT1-derived peptide is preferable. As specific WT1-derived peptide, RMFPNAPYL (SEQ ID NO: 1), SLGEQQYSV (SEQ ID NO: 2), CMTWNQMNL (SEQ ID NO: 3) (modified peptide thereof CYTWNQMNL (SEQ ID NO: 4)) and the like can be mentioned.

35 [0099]

In step (I) of the present invention (or the step (3)), MHC class II is not particularly limited as long as it is a molecule that forms a complex with an antigen peptide, is recognized by the CD3/TCR complex and CD4, and transmits a
5 signal into CD3-positive cells. MHC class II is, for example, HLA-DR, HLA-DQ or HLA-DP for human, and H-2A or H-2B for mouse, each of which is a dimer composed of α chain and β chain (e.g., HLA-DR is composed of HLA-DRA as α chain and HLA-DRB1 as β chain), preferably, HLA-DR, HLA-DQ or HLA-DP. The antigen
10 peptide is not particularly limited as long as it is a peptide presented by MHC class II. As the antigen peptide presented by MHC class II, for example, WT1, PSA, MAGE-3, CEA, survivin, tyrosinase, peptide derived from protein derived from a group of viruses strongly related to the development of malignant
15 tumor, and the like can be mentioned, and WT1-derived peptide is preferable.

[0100]

MHC and/or antigen peptide (hereinafter to be indicated as MHC and the like) may be a chemically-synthesized protein or
20 a protein biochemically synthesized in a cell-free translation system. Alternatively, the protein may be a recombinant protein produced from a transformant incorporating a nucleic acid having a base sequence that encodes MHC and the like.

[0101]

25 When MHC and the like are produced according to a known method of peptide synthesis, for example, any of a solid phase synthesis method and a liquid phase synthesis method may be used. The desired protein can be produced by condensing an amino acid derivative having a protecting group attached to a
30 carboxy group and a functional group of a side chain, and an amino acid derivative having a protected amino group and a protected functional group of a side chain, and removing the protecting groups.

Condensation and removal of protecting groups are
35 performed according to a method known per se, for example, the

methods described in (1) - (5) below.

(1) M. Bodanszky and M.A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966)

(2) Schroeder and Luebke: The Peptide, Academic Press, New York
5 (1965)

(3) Nobuo Izumiya, et al.: Peptide Gosei-no-Kiso to Jikken (Basics and experiments of peptide synthesis), published by Maruzen Co. (1975)

(4) Haruaki Yajima and Shunpei Sakakibara: Seikagaku Jikken
10 Koza (Biochemical Experiment) 1, Tanpakushitsu no Kagaku (Chemistry of Proteins) IV, 205 (1977)

(5) Haruaki Yajima, ed.: Zoku Iyaku hin no Kaihatsu (A sequel to Development of Pharmaceuticals), Vol. 14, Peptide Synthesis, published by Hirokawa Shoten.

15 [0102]

MHC and the like thus obtained can be purified or isolated by a known method of purification. Here, as examples of the method of purification, solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization,
20 combinations thereof and the like can be mentioned.

When the thus-obtained MHC and the like are in a free form, the free form can be converted into a suitable salt form by a known method or an analogue thereto, and on the other hand, when the MHC and the like are obtained in the form of a salt,
25 it can be converted into the free form or in the form of a different salt by a known method or an analogue thereto.

[0103]

Furthermore, MHC and the like can also be produced by culturing a transformant comprising a nucleic acid encoding the
30 same, and separating and purifying MHC and the like from the obtained culture. The nucleic acid that encodes MHC and the like may be DNA or RNA, or DNA/RNA chimera, and preferably DNA. In addition, the nucleic acid may be double-stranded or single-stranded. In the case of double strands, double-stranded DNA,
35 double-stranded RNA or DNA:RNA hybrid may be used. In the case

of a single strand, it may be a sense strand (that is, coding strand), or an antisense strand (that is, non-coding strand).
[0104]

Examples of the DNA encoding MHC and the like include
5 genome DNA, cDNA derived from cells of warm-blooded animal
(e.g., human, bovine, monkey, horse, swine, sheep, goat, dog,
cat, guinea pig, rat, mouse, rabbit, hamster, bird and the
like), synthetic DNA and the like. cDNA encoding MHC and the
like can be directly amplified by Polymerase Chain Reaction
10 (hereinafter to be abbreviated as "PCR method") by using, as a
template, a total RNA or mRNA fraction prepared from any cell
of the animals [e.g., hepatocyte, splenocyte, nerve cell, glial
cell, pancreatic β cell, myelocyte, mesangial cell, Langerhans'
cell, epidermal cell, epithelial cell, goblet cell, endothelial
15 cell, smooth muscle cell, fibroblast, fibrocyte, myocyte,
adipocyte, immunocyte (e.g., macrophage, T cell, B cell,
natural killer cell, mast cell, neutrophil, basophil,
eosinophil, monocyte), megakaryocyte, synovial cell,
chondrocyte, bone cell, osteoblast, osteoclast, mammary gland
20 cell, hepatocyte, interstitial cell, or a corresponding
progenitor cell, stem cell or cancer cell thereof etc.] or any
tissue in which these cells are present [e.g., brain or any
portion of brain (e.g., olfactory bulb, amygdaloid nucleus,
basal ganglia, hippocampus, thalamus, hypothalamus, cerebral
25 cortex, medulla oblongata, cerebellum), spinal cord, hypophysis,
stomach, pancreas, kidney, liver, gonad, thyroid, gallbladder,
bone marrow, adrenal gland, skin, lung, gastrointestinal tract
(e.g., large intestine and small intestine), blood vessel,
heart, thymus, spleen, submandibular gland, peripheral blood,
30 prostate, testis, ovary, placenta, uterus, bone, joint, adipose
tissue (e.g., brown adipose tissue, white adipose tissue),
skeletal muscle, etc.], and by Polymerase Chain Reaction
(hereinafter abbreviated as "PCR method") and Reverse
Transcriptase-PCR (hereinafter abbreviated as "RT-PCR method").
35 Alternatively, cDNA encoding MHC and the like can also be

cloned by colony or plaque hybridization method or PCR method and the like from a cDNA library prepared by inserting the above-mentioned total RNA or a fragment of mRNA into a suitable vector. The vector used for the library may be any of a
5 bacteriophage, a plasmid, a cosmid, a phagemid and the like.

[0105]

A DNA encoding MHC and the like can be cloned by amplifying a synthesized DNA primer having a part of a base sequence encoding the MHC and the like by PCR method, or
10 hybridizing a DNA incorporated into a suitable expression vector with a labeled DNA fragment or synthetic DNA encoding a part or whole region of MHC and the like. The hybridization can be performed by a method known per se or a method analogous thereto, for example, by the method described in Molecular
15 Cloning, 2nd ed. (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989) and the like. When a commercially available library is used, the hybridization can be performed according to the attached instruction manual. The hybridization can be preferably performed under stringent conditions.

20 [0106]

As examples of the highly stringent conditions, conditions of a hybridization reaction in 6×SSC (sodium chloride/sodium citrate) at 45°C followed by washing in 0.2×SSC/0.1% SDS at 65°C once or more and the like can be
25 mentioned. Those skilled in the art are able to easily obtain desired stringency by changing the salt concentration of the hybridization solution, hybridization reaction temperature, probe concentration, probe length, the number of mismatches, hybridization reaction time, the salt concentration of the
30 washing solution, washing temperature and the like as appropriate. When a commercially available library is used, hybridization can be conducted according to the method described in the instruction manual attached to the library.

[0107]

35 An expression vector comprising DNA that encodes MHC and

the like can be produced by, for example, cutting out a desired DNA fragment from the DNA that encodes MHC and the like, and joining the DNA fragment downstream of a promoter in an appropriate expression vector.

5 [0108]

As an expression vector, *Escherichia coli*-derived plasmids (e.g., pBR322, pBR325, pUC12, pUC13); animal cell expression plasmids (e.g., pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNA1/Neo); animal virus vectors such as retrovirus, vaccinia
10 virus, adenovirus, lentivirus and the like; and the like are used.

[0109]

The promoter may be any promoter, as long as it is appropriate for the host used to express the gene.

15 [0110]

For example, when the host is an animal cell, SR α promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Moloney murine leukaemia virus) LTR, HSV-TK (herpes simplex virus
20 thymidine kinase) promoter and the like are used. Of these, CMV promoter, SR α promoter and the like are preferred.

[0111]

When the host is a bacterium of the genus *Escherichia*, the trp promoter, the lac promoter, the recA promoter, the λ P_L
25 promoter, the lpp promoter, the T7 promoter and the like are preferred.

[0112]

Expression vectors used herein include, in addition to the above, expression vectors that optionally comprises an
30 enhancer, a splicing signal, a polyA addition signal, a selection marker, an SV40 replication origin (hereinafter also abbreviated as SV40 ori), and the like. As examples of the selection markers, the dihydrofolate reductase gene (hereinafter also abbreviated as dhfr) [methotrexate (MTX)
35 resistance], the ampicillin resistance gene (hereinafter also

abbreviated as amp^r), the neomycin resistance gene (hereinafter also abbreviated as neo^r , G418 resistance), and the like can be mentioned. In particular, when a dhfr gene defective Chinese hamster cell is used and the dhfr gene is used as the selection
5 marker, a target gene can also be selected using a thymidine-free medium.

[0113]

Where necessary, a base sequence encoding a signal sequence suitable for a host (signal codon) may be added (or
10 substituted with native signal codon) to the 5'-terminal side of a DNA encoding MHC and the like. For example, when the host is the genus *Escherichia*, PhoA signal sequence, OmpA signal sequence and the like are used; when the host is an animal cell, insulin signal sequence, α -interferon signal sequence, antibody
15 molecule signal sequence and the like are used.

[0114]

MHC and the like can be produced by transforming a host with an expression vector containing the above-mentioned DNA encoding MHC and the like, and culturing the obtained
20 transformant.

[0115]

As the host, for example, the genus *Escherichia*, animal cell and the like are used.

As the genus *Escherichia*, for example, K12 DH1 [Proc.
25 Natl. Acad. Sci. USA, vol. 60, 160(1968)], JM103 [Nucleic Acids Research, vol. 9, 309(1981)], JA221 [Journal of Molecular Biology, vol. 120, 517(1978)], HB101 [Journal of Molecular Biology, vol. 41, 459(1969)], C600 [Genetics, vol. 39, 440(1954)] and the like are used.

30 [0116]

As the animal cell, for example, monkey COS-7 cell, monkey Vero cell, Chinese hamster ovary cell (hereinafter to be abbreviated as CHO cell), dhfr gene defective CHO cell (hereinafter to be abbreviated as CHO(dhfr⁻) cell), mouse L
35 cell, mouse AtT-20 cell, mouse myeloma cell, rat GH3 cell,

human FL cell, and the like may be used.

[0117]

Transformation can be carried out according to the kind of host in accordance with a known method.

5 [0118]

The genus *Escherichia* can be transformed, for example, in accordance with the methods described in *Proc. Natl. Acad. Sci. USA*, vol. 69, 2110(1972), *Gene*, vol. 17, 107(1982) and the like.

10 [0119]

Animal cells can be transformed according to, for example, the method described in *Saibo Kogaku*, extra issue 8, *Shin Saibo Kogaku Jikken Protocol*, 263-267 (1995), published by Shujunsha, or *Virology*, 52, 456 (1973).

15 [0120]

Culture of a transformant can be carried out according to the kind of host in accordance with a known method.

[0121]

As an example of the medium used for culturing a transformant whose host is a bacterium of the genus *Escherichia*, a M9 medium supplemented with glucose and a cas amino acid [Miller, *Journal of Experiments in Molecular Genetics*, 431-433, Cold Spring Harbor Laboratory, New York 1972] is preferable. As required, in order to increase promoter efficiency, a chemical agent such as 3 β -indolylacrylic acid may be added to the medium.

[0122]

Cultivation of a transformant whose host is a bacterium of the genus *Escherichia* is normally carried out at about 15°C to about 43°C for about 3 to about 24 hours. Where necessary, the culture may be aerated or agitated.

[0123]

As a medium used when culturing a transformant whose host is an animal cell, for example, minimum essential medium (MEM) containing about 5 - about 20% fetal bovine serum [Science,

vol. 122, 501(1952)], Dulbecco's modified Eagle medium (DMEM) [Virology, vol. 8, 396(1959)], RPMI1640 medium [The Journal of the American Medical Association, vol. 199, 519(1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 5 vol. 73, 1(1950)] or the like is used. The medium's pH is preferably about 6 to about 8. Cultivation is normally carried out at about 30°C to about 40°C for about 15 to about 60 hours. As necessary, the culture may be aerated or agitated.

[0124]

10 As described above, MHC and the like can be produced in a cell of the transformant or outside the cell.

[0125]

MHC and the like can be separated and purified from the culture obtained by cultivating the transformant according to a 15 method known per se.

[0126]

For example, when MHC or the like is extracted from a cultured bacterium or cytoplasm of cell, a method is used as appropriate wherein bacteria or cells are collected from the 20 culture by a known means, suspended in an appropriate buffer solution, and disrupted by means of sonication, lysozyme and/or freeze-thawing and the like, after which a crude extract of soluble protein is obtained by centrifugation or filtration. The buffer solution may comprise a protein denaturing agent 25 such as urea or guanidine hydrochloride and a surfactant such as Triton X-100™. In addition, when MHC or the like is secreted outside the bacteria (cell), a method of separating a culture supernatant by centrifugation, filtration or the like from a culture, and the like are used.

30 [0127]

Isolation and purification of MHC and the like contained in the thus-obtained soluble fraction and culture supernatant can be conducted according to a method know per se. Useful methods include methods based on solubility, such as salting- 35 out and solvent precipitation; methods based mainly on

molecular weight differences, such as dialysis, ultrafiltration, gel filtration, and SDS-polyacrylamide gel electrophoresis; methods based on charge differences, such as ion exchange chromatography; methods based on specific affinity, such as affinity chromatography; methods based on hydrophobicity differences, such as reversed-phase high performance liquid chromatography; and methods based on isoelectric point differences, such as isoelectric focusing. These methods can be combined as appropriate.

10 [0128]

The MHC/antigen peptide complex obtained as described above may be a multimer. By multimerizing the MHC/antigen peptide complex, a higher agonist effect on TCR can be expected. The method for multimerizing the MHC/antigen peptide complex of the present invention is known. For example, the biotin-modified MHC/antigen peptide complex can be tetramerized via a tetramer of avidin or streptavidin. Alternatively, it can also be multimerized by ligating the MHC/antigen peptide complex to dextran.

20 [0129]

When the CD3/TCR complex agonist used in step (I) of the present invention (or the step (3)) is an MHC/superantigen complex, the MHC/superantigen complex is a complex of MHC class II and superantigen. As the superantigen, Staphylococcal enterotoxin, Streptococcal pyrogenic exotoxin, toxic shock syndrome toxin and the like can be mentioned. MHC and superantigen may be produced by a method the same as the method described for the MHC and the like. The MHC/superantigen complex may be a multimer like the MHC/antigen peptide complex. The method for multimerizing the MHC/superantigen complex of the present invention is the same as the method for multimerizing the MHC/antigen peptide complex.

[0130]

The CD3/TCR complex agonist used in step (I) of the present invention may be present in any form as long as it can

contact the CD3/TCR complex on the CD3-positive cellular surface during culture. For example, it may be contained in the medium during culture, or may be immobilized on a culture container, and is preferably immobilized on a culture container.

5 [0131]

When the CD3/TCR complex agonist is contained in the medium, the medium is not particularly limited as long as CD3-positive cells can be cultured therein. For example, Glasgow's Minimal Essential medium (GMEM) medium, IMDM medium, medium 199
10 medium, Eagle's Minimum Essential medium (EMEM) medium, α MEM medium, Dulbecco's modified Eagle's medium (DMEM) medium, Ham's F12 medium, RPMI 1640 medium, Fischer's medium, Neurobasal medium (Life Technologies) and mixed media of these, and the like are included. The medium may contain a serum, or may be
15 serum-free. When a serum is contained, the concentration of the serum (e.g., fetal bovine serum (FBS), human serum and the like) is such that the lower limit is generally not less than 1%, preferably not less than 5%, and the upper limit is generally not more than 20%, preferably not more than 15%.
20 Where necessary, the medium may contain one or more serum substitutes such as Knockout Serum Replacement (KSR) (serum replacement of FBS in culturing ES cells), N2 supplement (Invitrogen), B27 supplement (Invitrogen), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite),
25 vitamin Cs (e.g., ascorbic acid) apotransferrin, fatty acid, collagen precursor, trace element, 2-mercaptoethanol, 3'-thiolglycerol and the like, and one or more substances such as lipid, amino acid, L-glutamine, L-alanyl-L-glutamine (e.g., Glutamax (registered trade mark)), non-essential amino acid,
30 vitamin, growth factor, low-molecular-weight compound, antibiotic (e.g., penicillin, streptomycin), antioxidant, pyruvic acid, buffering agent, inorganic salts, selenium acid, progesterone, putrescine and the like. When the CD3/TCR complex agonist is contained in the medium, the concentration
35 of the CD3/TCR complex agonist may be such that the lower limit

is not less than 0.3 ng/ml, preferably not less than 3 ng/ml, and the upper limit is not more than 10000 ng/ml, preferably not more than 1000 ng/ml. Particularly, when the CD3/TCR complex agonist is an anti-CD3 agonist antibody, the
5 concentration of the anti-CD3 agonist antibody in the medium is, for example, 10 ng/ml - 1000 ng/ml. The culture can be performed, for example, in a CO₂ incubator under a CO₂ concentration atmosphere of about 1 - about 10%, preferably about 2 - about 5% at about 30 - about 40°C, preferably about
10 37°C. The culture period in a medium containing CD3/TCR complex agonist can be appropriately determined by those skilled in the art by monitoring the number of CD3-positive cells and the like. The number of days is not limited as long as CD3-positive cells can be obtained. The culture period is,
15 for example, at least 6 hr or more, 12 hr or more, 16 hr or more, 24 hr or more, 48 hr or more, 72 hr or more, preferably 16 - 72 hr. In addition, 14 days or more is preferable, and 7 days or more is more preferable.

[0132]

20 When Vitamin C is used, the Vitamin C is preferably added (supplied) every four days, every three days, every two days, or every day. Vitamin C is more preferably added every day. In one embodiment, Vitamin C is preferably added to the medium at an amount corresponding to 5 ng/ml to 500 ng/ml (e.g., an
25 amount corresponding to 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, or 500 ng/ml). In another embodiment, Vitamin C is added to the culture medium at an amount corresponding to 5 µg/ml - 500 µg/ml (e.g., an amount corresponding to 5 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 100
30 µg/ml, 200 µg/ml, 300 µg/ml, 400 µg/ml, 500 µg/ml).

[0133]

The medium used in step (I) of the present invention may further contain cytokine. The cytokine contained in the medium is not particularly limited and at least one selected from IL-7,
35 IL-15, IL-18 and IL-21 can be mentioned. It is preferable to

contain all of IL-7, IL-15, IL-18 and IL-21. The concentration of cytokine is such that the lower limit is not less than 0.1 ng/mL, preferably not less than 10 ng/mL, and the upper limit is not more than 1000 ng/mL, preferably not more than 300 ng/mL.

5 When these cytokines are used, the concentration in the medium is 1 - 100 ng/ml for IL-7, 1 - 100 ng/ml for IL-15, 5 - 500 ng/ml for IL-18, and 2 - 200 ng/ml for IL-21.

The medium used in step (I) of the present invention may further contain TL1A and/or IL-12. In this case, the
10 concentration of TL1A in the medium is 5 - 500 ng/ml, and the concentration of IL-12 in the medium is 5 - 500 ng/ml.

[0134]

The medium used in step (I) of the present invention may contain a TNF family cytokine as cytokine. Examples of the TNF
15 family cytokine include TNF- α , TNF- β , lymphotoxin α , Fas ligand, TRAIL, TWEAK, TL1A, RANK ligand, OX40 ligand, APRIL, AITRL, BAFF, 4-1BBL and CD40 ligand and the like, and TL1A is preferable. When TL1A is used, the concentration thereof in the medium may be 5 ng/ml - 500 ng/ml.

20 [0135]

As the apoptosis inhibitor used in step (I) of the present invention, a protease inhibitor, for example, caspase inhibitor, can be mentioned. As the caspase inhibitor, Pan Caspase FMK inhibitor Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp(O-
25 Me) fluoromethylketone) is preferable, and the concentration thereof in the medium may be 1 - 1000 μ M.

[0136]

When the CD3/TCR complex agonist is immobilized on a culture container, the culture container is not particularly
30 limited as long as CD3-positive cells can be cultured therein, and container, slide, bead or a combination of these can be used. Examples of the culture container include flask, tissue culture flask, dish, petri dish, tissue culture dish, multidish, microplate, microwell plate, multiplate, muliwell plate, micro
35 slide, chamber slide, petri dish, tube, tray, culture bag,

roller bottle, micro bead and the like.

[0137]

The CD3/TCR complex agonist can be immobilized on a culture container by a known means. For example, a CD3/TCR complex agonist can be immobilized on a culture container by dissolving the CD3/TCR complex agonist in a solvent (e.g., PBS and the like), adding same to the culture container, and allowing to stand at 4°C overnight. The concentration of the CD3/TCR complex agonist solution for immobilizing the CD3/TCR complex agonist on the culture container can be appropriately determined by those skilled in the art according to the kind of the CD3/TCR complex agonist. In one embodiment of the present invention, for example, when the CD3/TCR complex agonist is an anti-CD3 agonist antibody or a binding fragment thereof, a 0.3 - 10000 ng/ml solution of the anti-CD3 agonist antibody or a binding fragment thereof can be generally contacted with the culture container, and 3 - 5000 ng/ml is more preferable, 3 - 3000 ng/ml is further preferable, and 3 - 600 ng/ml is particularly preferable. In another embodiment of the present invention, the concentration of an anti-CD3 agonist antibody or a binding fragment thereof in a solution is, for example, 10 ng/ml - 10000 ng/ml, preferably 50 ng/ml - 5000 ng/ml, more preferably 200 ng/ml - 4000 ng/ml. In still another embodiment of the present invention, the concentration of an anti-CD3 agonist antibody or a binding fragment thereof in a solution is, for example, 1 - 50000 ng/ml, preferably 3 - 30000 ng/ml, more preferably 30 - 30000 ng/ml, further preferably 300 - 30000 ng/ml. When the anti-CD3 agonist antibody or a binding fragment thereof is an antibody (OKT3) or a binding fragment thereof produced from an OKT3 clone, the concentration thereof in a solution is, for example, 1 ng/ml - 50000 ng/ml, preferably 10 ng/ml - 10000 ng/ml, more preferably 50 ng/ml - 5000 ng/ml, further preferably 200 ng/ml - 4000 ng/ml. When the anti-CD3 agonist antibody or a binding fragment thereof is an antibody (UCHT1) or a binding fragment thereof produced from

a UCHT1 clone, the concentration thereof in a solution is, for example, 1 ng/ml - 50000 ng/ml, preferably 3 ng/ml - 30000 ng/ml, more preferably 30 ng/ml - 30000 ng/ml, further preferably 300 ng/ml - 30000 ng/ml.

5 [0138]

In step (I) of the present invention, fibronectin is not particularly limited as long as it is a molecule capable of binding to CD3-positive cells. The variant of fibronectin is not particularly limited as long as it is a molecule capable of
10 binding to VLA-5 and VLA-4 on the surface of CD3-positive cells, and examples thereof include RetroNectin (registered trade mark).

[0139]

Fibronectin or a variant thereof to be used in step (I)
15 of the present invention may be present in any form as long as they can contact CD3-positive cells during culture, like the CD3/TCR complex agonist. For example, they may be contained in the medium during culture, or may be immobilized on a culture container, and are preferably immobilized on a culture
20 container.

[0140]

When fibronectin or a variant thereof is contained in a medium, the medium may be the same as that containing a CD3/TCR complex agonist. The presence or absence of serum, additive
25 and the like may be the same as that in the medium containing a CD3/TCR complex agonist. When fibronectin or a variant thereof is contained in a medium, the lower limit of the concentration of fibronectin or a variant thereof may be not less than 10 ng/ml, preferably not less than 100 ng/ml, and the upper limit
30 may be not more than 10000 µg/ml, preferably not more than 1000 µg/ml.

[0141]

When fibronectin or a variant thereof is immobilized on a culture container, the culture container may be the same as
35 that on which the CD3/TCR complex agonist is immobilized. In

addition, immobilization of fibronectin or a variant thereof on the culture container may be the same as that of immobilizing the CD3/TCR complex agonist. The immobilizing of fibronectin or a variant thereof on a culture container may be the same as
5 that of CD3/TCR complex agonist. The concentration of the solution of fibronectin or a variant thereof when immobilizing fibronectin or a variant thereof on a culture container may be appropriately determined by those skilled in the art according to the fibronectin or a variant thereof. For example, when
10 fibronectin or a variant thereof is RetroNectin (registered trade mark), a solution of 0.1 - 10000 µg/mL of RetroNectin (registered trade mark) is preferably contacted with the culture container. In this case, the concentration of the RetroNectin solution is more preferably 0.1 - 1000 µg/mL,
15 further preferably 1 - 300 µg/mL, particularly preferably 1 - 150 µg/mL.

[0142]

In step (I) of the present invention, the CD30 agonist is not particularly limited as long as it is a molecule capable of
20 transducing a signal from a CD30 into a cell by specifically binding to CD30. Examples of the CD30 agonist include at least one selected from the group consisting of anti-CD30 agonist antibody or a fragment bonded thereto and CD30 ligand or a fragment bonded thereto.

25 [0143]

The kind, production method and the like of the anti-CD30 agonist antibody and a binding fragment thereof used in step (I) of the present invention may be the same as those of the anti-CD3 agonist antibody and anti-TCR antibody.

30 [0144]

The CD30 ligand or a binding fragment thereof used in step (I) of the present invention is, for example, CD153. The CD30 ligand or a binding fragment thereof may be produced by a method similar to the production method of MHC and/or antigen
35 peptide.

[0145]

The CD30 agonist used in step (I) of the present invention may be present in any form as long as it can be present in contact with CD30 during culturing. For example, it
5 may be contained in the medium during culture, or may be immobilized on a culture container, and is preferably contained in the medium.

[0146]

When a CD30 agonist is contained in a medium, the medium
10 may be the same as that containing a CD3/TCR complex agonist. The presence or absence of serum, additive and the like may be the same as that in the medium containing a CD3/TCR complex agonist. When a CD30 agonist is contained in a medium, the concentration of the CD30 agonist in the medium can be
15 appropriately determined by those skilled in the art according to the kind of the CD30 agonist. For example, when the CD30 agonist is an anti-CD30 agonist antibody or a binding fragment thereof, the concentration of the anti-CD30 agonist antibody or a binding fragment thereof in the medium is generally 1 ng/ml -
20 10000 ng/ml, preferably 1 ng/ml - 1000 ng/ml, more preferably 3 ng/ml - 300 ng/ml, further preferably 30 ng/ml - 300 ng/ml.

[0147]

When the CD30 agonist is immobilized on a culture container, the culture container may be the same as that on
25 which the CD3/TCR complex agonist is immobilized. In addition, a method of immobilizing the CD30 agonist on the culture container may be the same as that of immobilizing the CD3/TCR complex agonist. The lower limit of the concentration of a CD30 agonist solution when the CD30 agonist is immobilized on a
30 culture container may be not less than 0.1 ng/ml, preferably not less than 1 ng/ml, and the upper limit may be not more than 10000 ng/ml, preferably not more than 1000 ng/ml.

[0148]

The production method or expansion culture method of the
35 present invention may further include a step of culturing the

CD3-positive cells, which were cultured in step (I) of the present invention, in the absence of a CD3/TCR complex agonist, and fibronectin or a variant thereof, and in the presence of a CD30 agonist (hereinafter to be referred to as step (II) of the present invention).

[0149]

As the medium in step (II) of the present invention, the medium used in the above-mentioned step (I) can be used. The medium may contain a serum, or may be serum-free. When a serum is contained, the concentration of the serum (e.g., fetal bovine serum (FBS), human serum and the like) is such that the lower limit is generally not less than 1%, preferably not less than 5%, and the upper limit is generally not more than 20%, preferably not more than 15%. Where necessary, the medium may contain one or more serum substitutes such as Knockout Serum Replacement (KSR) (serum replacement of FBS in culturing ES cells), N2 supplement (Invitrogen), B27 supplement (Invitrogen), albumin, insulin, transferrin, selenium compounds (e.g., sodium selenite), vitamin Cs (e.g., ascorbic acid) apotransferrin, fatty acid, collagen precursor, trace element, 2-mercaptoethanol, 3'-thiolglycerol and the like, and one or more substances such as lipid, amino acid, L-glutamine, Glutamax (Invitrogen), non-essential amino acid, vitamin, growth factor, low-molecular-weight compound, antibiotic, antioxidant, pyruvic acid, buffering agent, inorganic salts, selenium acid, progesterone, putrescine and the like. The culture can be performed, for example, in a CO₂ incubator under a CO₂ concentration atmosphere of about 1 - about 10%, preferably about 2 - about 5% at about 30 - about 40°C, preferably about 37°C. The culture period can be appropriately determined by those skilled in the art by monitoring the number of CD3-positive cells and the like. The number of days is not limited as long as CD3-positive cells can be obtained. The culture period is, for example, not less than 3 days, not less than 5 days, not less than 7 days, not less than 10 days, not less

than 14 days, not less than 21 days, preferably not less than 5 days and not more than 15 days. It is preferably not more than 30 days, more preferably not more than 21 days.

[0150]

5 When Vitamin C is used, the Vitamin C is preferably added (supplied) every four days, every three days, every two days, or every day. The Vitamin C is more preferably added every day. In one embodiment, Vitamin C is added to the medium at an amount corresponding to 5 ng/ml to 500 ng/ml (e.g., an amount
10 corresponding to 5 ng/ml, 10 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml, 300 ng/ml, 400 ng/ml, or 500 ng/ml). In another embodiment, Vitamin C is added to the culture medium at an amount corresponding to 5 µg/ml - 500 µg/ml (e.g., an amount corresponding to 5 µg/ml, 10 µg/ml, 25 µg/ml, 50 µg/ml, 100
15 µg/ml, 200 µg/ml, 300 µg/ml, 400 µg/ml, 500 µg/ml).

[0151]

 The medium used in step (II) of the present invention may further contain cytokine. The cytokine is not particularly limited and at least one selected from IL-7, IL-15, IL-18 and
20 IL-21 can be mentioned. It is preferable to contain all of IL-7, IL-15, IL-18 and IL-21. The concentration of cytokine may be such that the lower limit is not less than 0.1 ng/mL, preferably not less than 10 ng/mL, and the upper limit is not more than 1000 ng/mL, preferably not more than 300 ng/mL. When
25 these cytokines are used, the concentration in the medium may be 1 ng/ml - 100 ng/ml for IL-7, 1 ng/ml - 100 ng/ml for IL-15, 5 ng/ml - 500 ng/ml for IL-18, and 2 ng/ml - 200 ng/ml for IL-21.

 The medium used in step (II) of the present invention may
30 further contain TL1A and/or IL-12. In this case, the concentration of TL1A in the medium may be 5 ng/ml - 500 ng/ml, and the concentration of IL-12 in the medium may be 5 ng/ml - 500 ng/ml.

[0152]

35 The medium used in step (II) of the present invention may

further contain an apoptosis inhibitor. As the apoptosis inhibitor, a protease inhibitor can be mentioned, for example, caspase inhibitor. As the caspase inhibitor, Pan Caspase FMK inhibitor Z-VAD (N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone) (hereinafter sometimes referred to as "Z-VAD-FMK") is preferable, and the concentration thereof in the medium may be 1 μ M - 1000 μ M, preferably 1 μ M - 500 μ M, more preferably 1 μ M - 200 μ M, particularly preferably 1 μ M - 50 μ M.
[0153]

10 In one embodiment of the present invention, the above-mentioned step (I) and step (II) may be repeated in this order.
[0154]

The present invention also provides CD3-positive cells obtained by the production method or expansion culture method of the present invention (hereinafter to be referred to as the CD3-positive cell of the present invention). The CD3-positive cell of the present invention is the same as the CD3-positive cell obtained by the production method or expansion culture method of the present invention.

20 [0155]

The present invention also provides a kit for expansion culture of CD3-positive cells containing the following (hereinafter to be referred to as the kit of the present invention):

- 25 (1) a culture container having a CD3/TCR complex agonist, and fibronectin or a variant thereof immobilized thereon, and
(2) a medium containing a CD30 agonist.

[0156]

30 The CD3/TCR complex agonist, fibronectin or a variant thereof, CD30 agonist, culture container and medium contained in the kit of the present invention may be the same as those described for the production method or expansion culture method of the present invention.

35 [0157]

The present invention also provides a method for maintaining CD3-positive cells as CD3-positive CD197-positive cells, including a step of stimulating a CD30 signal in the CD3-positive cells (hereinafter to be referred to as the
5 maintaining method of the present invention).

Generally, when peripheral blood-derived naive T cells are stimulated with an antigen presented by dendritic cell, naive T cells are activated by intracellular signals, repeat proliferation and maturation, and sequentially differentiate
10 into stem cell memory T cells, central memory T cells, effector memory T cells, and effector T cells. Effector T cells produce cytokine in the case of CD3-positive CD4-positive CD8-negative cells (helper T cells), and kill target cells via antigen in the case of CD3-positive CD4-negative CD8-positive cell
15 (cytotoxic T cell), but cannot survive for a long time. However, by stimulating the CD30 signal in T cells, the T cells can be maintained as self-proliferating naive T cells or stem cell memory T cells (CD197-positive, CD45RA-positive) or central memory T cells (CD197-positive, CD45RA-negative) that
20 can differentiate into effector T cells.

[0158]

The CD3-positive cells cultured by the maintaining method of the present invention may be the same as the CD3-positive cells cultured by, the production method or expansion culture
25 method of the present invention. Preferably, the CD3-positive cell is a CD3-positive CD197-positive cell.

[0159]

The maintaining method of the present invention includes a step of stimulating the CD30 signal in the CD3-positive cells.
30 The method of stimulating the CD30 signal in the CD3-positive cells is not particularly limited as long as the signal can be transmitted to the downstream via an intracellular domain of CD30. Examples of the method include a method including a step of culturing CD3-positive cells in the presence of a CD30
35 agonist (hereinafter to be referred to as the maintaining

method (1) of the present invention). The CD3-positive cell can be maintained as CD3-positive CD197-positive cells by the maintaining method (1) of the present invention.

In one embodiment of the maintaining method (1) of the present invention, CD3-positive cells can be maintained as CD3-positive CD197-positive CD45RA-negative cells.

The CD30 agonist and culture conditions used in the maintaining method (1) of the present invention may be the same as those used in the production method or expansion culture method of the present invention.

[0160]

The present invention also provides a kit containing a CD30 agonist for maintaining CD3-positive cells as CD3-positive CD197-positive cells (hereinafter to be referred to as the maintaining kit of the present invention).

[0161]

The CD30 agonist contained in the maintaining kit of the present invention may be the same as the CD30 agonist used in the maintaining method (1) of the present invention.

[0162]

In the maintaining method of the present invention, another method for stimulating a CD30 signal in the CD3-positive cell is, for example, a method including a step of culturing CD3-positive cells that express a chimeric antigen receptor containing the intracellular domain of CD30, in the presence of an antigen that stimulates the chimeric antigen receptor (hereinafter to be referred to as the maintaining method (2) of the present invention). The signal can be transmitted to the downstream via an intracellular domain of CD30 by stimulating a chimeric antigen receptor containing the intracellular domain of CD30, and CD3-positive cells that express a chimeric antigen receptor containing the intracellular domain of CD30 can be maintained as CD3-positive CD197-positive cells.

In one embodiment of the maintaining method (2) of the

present invention, CD3-positive cells that express a chimeric antigen receptor containing the intracellular domain of CD30 can be maintained as CD3-positive CD197-positive CD45RA-negative cells.

5 The culture conditions used in the maintaining method (2) of the present invention may be the same as those used in the production method or expansion culture method of the present invention.

[0163]

10 The antigen that stimulates the chimeric antigen receptor used in the maintaining method (2) of the present invention is not particularly limited as long as a signal can be transmitted to the downstream via an intracellular domain of CD30 contained in the chimeric antigen receptor. The antigen
15 that stimulates the chimeric antigen receptor may be the same as the antigen targeted by the chimeric antigen receptor of the chimeric antigen receptor-expressing CD3-positive cells cultured by the production method or expansion culture method of the present invention.

20 [0164]

 The present invention also provides a chimeric antigen receptor containing an antigen binding domain, a transmembrane domain and an intracellular signal transduction domain, wherein the intracellular signal transduction domain contains an
25 intracellular domain of CD30 or a mutant thereof (hereinafter to be referred to as the chimeric antigen receptor of the present invention).

[0165]

 The antigen binding domain contained in the chimeric
30 antigen receptor of the present invention may be the same as the antigen binding domain contained in the chimeric antigen receptor expressed on the CD3-positive cells cultured in the production method or expansion culture method of the present invention.

35 [0166]

The transmembrane domain contained in the chimeric antigen receptor of the present invention may be the same as the transmembrane domain contained in a chimeric antigen receptor expressed on the CD3-positive cells cultured in the
5 production method or expansion culture method of the present invention.

[0167]

The intracellular signal transduction domain contained in the chimeric antigen receptor of the present invention contains
10 an intracellular domain of CD30 or a mutant thereof. The intracellular domain of CD30 is not particularly limited as long as the antigen binding domain contained in the chimeric antigen receptor of the present invention recognizes an antigen and retains the function of transmitting the recognition signal
15 thereof into cells. For example, a peptide containing the amino acid sequence shown in SEQ ID NO: 6 can be mentioned.

[0168]

While the mutant of the intracellular domain of CD30 is not particularly limited as long as it can retain the above-
20 mentioned function, for example, a peptide containing an amino acid sequence having a homology of not less than about 90%, preferably not less than about 95%, more preferably not less than about 97%, particularly preferably not less than about 98%, most preferably not less than about 99%, with the amino acid
25 sequence shown in SEQ ID NO: 6 can be mentioned. As used herein, the "homology" may be the same as that in the amino acid sequence of "IL-15/IL-15R α ".

[0169]

In addition, the mutant of the intracellular domain of
30 CD30 also includes, for example, a protein containing (1) an amino acid sequence wherein one or more (preferably, 1 - about 100, preferably 1 - about 50, further preferably 1 - about 10, particularly preferably 1 - several (2, 3, 4 or 5)) amino acids in the amino acid sequence shown in SEQ ID NO: 6 are deleted,
35 (2) an amino acid sequence wherein one or more (preferably, 1 -

about 100, preferably 1 - about 50, further preferably 1 -
about 10, particularly preferably 1 - several (2, 3, 4 or 5))
amino acids are added to the amino acid sequence shown in SEQ
ID NO: 6, (3) an amino acid sequence wherein one or more
5 (preferably, 1 - about 50, preferably 1 - about 10, further
preferably 1 - several (2, 3, 4 or 5)) amino acids are inserted
into the amino acid sequence shown in SEQ ID NO: 6, (4) an
amino acid sequence wherein one or more (preferably, 1 - about
50, preferably 1 - about 10, further preferably 1 - several (2,
10 3, 4 or 5)) amino acids are substituted by other amino acids in
the amino acid sequence shown in SEQ ID NO: 6 or (5) an amino
acid sequence which is a combination thereof and the like.
When the amino acid sequence is inserted, deleted or
substituted as mentioned above, the position of insertion or
15 deletion or substitution is not particularly limited as long as
the function of the intracellular domain of CD30 is maintained.
[0170]

The intracellular signal transduction domain contained in
the chimeric antigen receptor of the present invention may
20 contain an intracellular domain of CD30 or a mutant thereof,
and further an intracellular domain derived from other protein.
The intracellular domain to be further contained may be the
same as the intracellular domain contained in an intracellular
signal transduction domain contained in the chimeric antigen
25 receptor expressed on CD3-positive cells cultured in the
production method or expansion culture method of the present
invention. The intracellular domain to be further contained is
not particularly limited, and an intracellular domain derived
from CD28 or CD3 ζ chain is preferable.

30 [0171]

The chimeric antigen receptor of the present invention
may have a spacer incorporated in between an antigen binding
domain and a transmembrane domain, or between an intracellular
signal transduction domain and a transmembrane domain. The
35 spacer may be the same as the spacer contained in the chimeric

antigen receptor expressed on CD3-positive cells cultured in the production method or expansion culture method of the present invention.

[0172]

5 Specific examples of the chimeric antigen receptor of the present invention include a chimeric antigen receptor containing scFv recognizing CD19 as an antigen binding domain, transmembrane domain of CD8 as a transmembrane domain, intracellular domain derived from CD28 as an intracellular
10 signal transduction domain, an intracellular domain derived from CD30, and an intracellular domain derived from CD3 ζ chain. The order of the above-mentioned intracellular domains contained in the intracellular signal transduction domain is not particularly limited and, for example, the order of the
15 intracellular domain derived from CD28, the intracellular domain derived from CD30, and the intracellular domain derived from CD3 ζ chain is adopted. More specifically, the chimeric antigen receptor in the present invention is composed of, for example, the amino acid sequence shown in SEQ ID NO: 7.

20 [0173]

 The chimeric antigen receptor of the present invention may be a chemically-synthesized protein or a protein biochemically synthesized in a cell-free translation system, or may be a recombinant protein produced from a transformant
25 incorporating a nucleic acid having a base sequence that encodes the chimeric antigen receptor of the present invention. The chimeric antigen receptor of the present invention can be similarly produced and isolated and purified according to the production method of MHC and/or antigen peptide used in the
30 production method or expansion culture method of the present invention.

[0174]

 The present invention also provides a nucleic acid containing a polynucleotide encoding the chimeric antigen
35 receptor of the present invention (hereinafter to be referred

to as the nucleic acid of the present invention).

[0175]

The nucleic acid of the present invention may be a DNA or an RNA, or DNA/RNA chimera. Preferred is a DNA. In addition, the nucleic acid may be double-stranded or single-stranded. In the case of double strands, double-stranded DNA, double-stranded RNA or DNA:RNA hybrid may be used. In the case of single strand, it may be a sense strand (i.e., coding strand), or an antisense strand (i.e., non-coding strand).

10 [0176]

The nucleic acid of the present invention can be obtained by the Polymerase Chain Reaction (hereinafter abbreviated as "PCR method"). First, a genome DNA or cDNA encoding each domain of an antigen binding domain, a transmembrane domain and an intracellular signal transduction domain contained in the chimeric antigen receptor of the present invention. cDNA can also be directly amplified by PCR method and Reverse Transcriptase-PCR (hereinafter to be abbreviated as "RT-PCR method") by using, as a template, a total RNA or mRNA fraction prepared from cells. Using the obtained genome DNA or cDNA as a template, a nucleic acid encoding each domain of an antigen binding domain, a transmembrane domain and an intracellular signal transduction domain can be amplified by the PCR method using a synthetic DNA primer consisting of a part of the base sequence encoding each domain and a base sequence encoding a spacer. The nucleic acid of the present invention can be obtained by repeating the PCR method using the obtained respective domains as templates, and the synthetic DNA primers.

[0177]

30 The present invention also provides a chimeric antigen receptor gene transfer vector containing the nucleic acid of the present invention (hereinafter to be referred to as the transgene vector of the present invention).

[0178]

35 The transgene vector of the present invention can be

produced, for example, by linking the nucleic acid of the present invention to the downstream of a promoter in an appropriate gene transfer vector. The gene transfer vector, promoter, and other elements may be the same as vector,
5 promoter, and other elements used when introducing exogenous TCR into pluripotent stem cells in the production method or expansion culture method of the present invention.
[0179]

The present invention also provides a chimeric antigen
10 receptor-expressing cell containing the transgene vector of the present invention (hereinafter to be referred to as the chimeric antigen receptor-expressing cell of the present invention).
[0180]

15 The chimeric antigen receptor-expressing cell of the present invention can be produced by introducing the transgene vector of the present invention into cells and culturing the cells. As the cell into which the transgene vector of the present invention is introduced, a CD3-positive cell or a
20 progenitor cell thereof (hematopoietic stem cell, common lymphoid progenitor cell, lymphoblast and the like), or a pluripotent stem cell can be mentioned. As the pluripotent stem cell, ES cell, iPS cell, EC cell, and EG cell can be mentioned, and ES cell or iPS cell is preferred.

25 [0181]

The transgene vector of the present invention may be introduced into cells by methods such as lipofection, liposome, microinjection and the like.

[0182]

30 The chimeric antigen receptor-expressing cell of the present invention is preferably a CD3-positive cell. The CD3-positive cell is preferably a CD3-positive CD8-positive cell (CD3-positive CD8-positive CD4-positive cell or CD3-positive CD8-positive CD4-negative cell), more preferably a CD3-positive
35 CD8-positive CD4-negative cell. Another preferable CD3-

positive cell mentioned above is, for example, a CD3-positive CD4-positive cell (CD3-positive CD4-positive CD8-positive cell or CD3-positive CD4-positive CD8-negative cell).

[0183]

5 When the chimeric antigen receptor-expressing cell of the present invention is a cell produced by introducing the transgene vector of the present invention into pluripotent stem cells, the pluripotent stem cell can be differentiated into a CD3-positive cell according to a method known per se. A
10 specific method for differentiating a pluripotent stem cell into a CD3-positive cell may be the same as the method for differentiating the CD3-positive cell to be cultured into a pluripotent stem cell in the production method or expansion culture method of the present invention.

15 [0184]

 The thus-obtained chimeric antigen receptor-expressing cell of the present invention is imparted with the specificity for the antigen of interest by the chimeric antigen receptor, and can show cytotoxic activity against tumors expressing the
20 antigen of interest. The chimeric antigen receptor can directly recognize an antigen molecule without relying on HLA class I or class II. Thus, the chimeric antigen receptor-expressing cell of the present invention can cause a high immune response even for tumors with reduced expression of HLA
25 class I or class II gene.

 Therefore, the present invention also provides a medicament containing the chimeric antigen receptor-expressing cell of the present invention as an active ingredient (hereinafter sometimes to be referred to as the medicament of
30 the present invention). A medicament containing the chimeric antigen receptor-expressing cell of the present invention can be used for the prophylaxis or treatment of tumors expressing an antigen recognized by the chimeric antigen receptor of the present invention, and can be administered, for example, to
35 mammals (e.g., mouse, rat, hamster, rabbit, cat, dog, bovine,

sheep, monkey, human), preferably human. Therefore, in one embodiment of the present invention, the medicament of the present invention for use for the prophylaxis or treatment of tumors expressing an antigen recognized by the chimeric antigen
5 receptor of the present invention is provided. In addition, a method for preventing or treating tumors expressing an antigen recognized by the chimeric antigen receptor of the present invention, including administering the chimeric antigen receptor-expressing cell of the present invention preferably in
10 the form of a medicament containing the cell is provided.
[0185]

The tumor that can be prevented or treated by the chimeric antigen receptor expression cell of the present invention is not particularly limited as long as it expresses
15 an antigen recognized by the chimeric antigen receptor of the present invention. Tumor is described in, for example, "Daniel Baumhoer et al., Am J. Clin Pathol, 2008, 129, 899-906" and the like. Tumor includes benign tumor, malignant tumor (also referred to as "cancer"), and tumor that may be diagnosed or
20 determined to be benign or malignant. Specific examples of tumor include, but are not limited to, liver cancer (e.g., hepatoma), ovarian cancer (e.g., ovary clear cell adenocarcinoma), childhood cancer, lung cancer (e.g., squamous cell carcinoma, small cell lung cancer), testis cancer (e.g.,
25 nonseminomas germ cell tumor), soft tissue tumor (e.g., liposarcoma, malignant fibrous histiocytoma), uterine cancer (e.g., cervix intraepithelial tumor, cervix squamous cell carcinoma), melanoma, adrenal gland tumor (e.g., adrenal gland adenoma), neurotic tumor (e.g., schwannoma), gastric cancer
30 (e.g., adenocarcinoma of stomach), renal cancer (e.g., Grawitz tumor), breast cancer (e.g., invasive lobular carcinoma, mucous cancer), thyroid cancer (e.g., medullar cancer), laryngeal cancer (e.g., squamous cell carcinoma), urinary bladder cancer (e.g., invasive transitional cell carcinoma) and the like.

35 [0186]

The chimeric antigen receptor-expressing cell of the present invention may be cultured and/or stimulated using an appropriate medium and/or a stimulating molecule before administration to a test subject. Examples of the stimulating molecule include, but are not limited to, cytokines, suitable protein, other components and the like. Examples of the cytokines include IL-2, IL-7, IL-12, IL-15, IFN- γ and the like, and IL-2 can be preferably used. While the concentration of IL-2 in the medium is not particularly limited, for example, it is preferably 0.01 U/mL - 1×10^5 U/mL, more preferably 1 U/mL - 1×10^4 U/mL. Examples of the suitable protein include an antigen recognized by chimeric antigen receptor, CD3 ligand, CD28 ligand, anti-CD3 antibody, anti-CD30 antibody, and anti-IL-4 antibody. Besides these, a lymphocyte stimulating factor such as lectin and the like can also be added. Furthermore, serum or plasma may be added to the medium. While the amount of addition to these media is not particularly limited, 0% by volume - 20% by volume can be mentioned. In addition, the amount of serum or plasma to be used can be changed according to the culturing stage. For example, serum or plasma concentration can be reduced stepwise. The origin of serum or plasma may be either autologous or allogeneic, and autologous one is preferable from the aspect of safety.

[0187]

The medicament of the present invention is preferably used by parenteral administration to the test subject. Examples of the method for parenteral administration include intravenous, intraarterial, intramuscular, intraperitoneal, and subcutaneous administration and the like. While the dose is appropriately selected according to the condition, body weight, age and the like of the test subject, the medicament is generally administered such that the cell number is generally 1×10^6 - 1×10^{10} cells, preferably 1×10^7 - 1×10^9 cells, more preferably 5×10^7 - 5×10^8 cells, per dose to a test subject with body weight 60 kg. The T cells may be administered once or in

plural portions. The medicament of the present invention can be formulated into a known form suitable for parenteral administration, for example, injection or injecting agent. The medicament of the present invention may contain saline, phosphate buffered saline (PBS), medium and the like to maintain the cells stably. The medium is not particularly limited, and examples thereof include, but are not limited to, media such as RPMI, AIM-V, X-VIVO10 and the like. The medicament may contain a pharmaceutically acceptable carrier (e.g., human serum albumin), preservative and the like for stabilizing purposes.

[0188]

Furthermore, since the chimeric antigen receptor-expressing cell of the present invention can kill cells that express an antigen recognized by the chimeric antigen receptor of the present invention, it can be used as a killing agent for cells expressing the antigen. Such killing agent can be produced and used in the same manner as the medicament.

[0189]

The present invention also includes embodiments of the use of the chimeric antigen receptor-expressing cell of the present invention in the production of prophylactic or therapeutic agents for tumor that expresses an antigen recognized by the chimeric antigen receptor of the present invention, according to the medicament containing the chimeric antigen receptor-expressing cell of the present invention. Prophylactic or therapeutic agents for tumor can be produced by a method known per se. For example, they can be produced in a known form suitable for parenteral administration, such as injection, injectable agent, or the like, as in the above-mentioned preparation method of the medicament of the present invention.

[0190]

While the present invention is explained in more detail in the following by referring to Examples, they are mere

exemplifications and do not limit the present invention.

[Example]

[0191]

[Example 1]

5 1. Preparation of iPS cell

As the iPS cell, Ff-I01s04 strain provided by the Center for iPS Cell Research and Application (CiRA), Kyoto University, was used. iPS cell culture was performed according to the protocol distributed by CiRA, "Human iPS cell culture under
10 feeder-free conditions".

[0192]

2. Introduction of T cell receptor (TCR) gene into iPS cell

As TCR gene, TAK1-derived HLA-A*24:02-restricted WT1-specific TCR (WT1-TCR) gene supplied by Professor Masataka
15 Yasukawa, Graduate School of Medicine, Ehime University, was used. Gene transfer into iPS cells was performed by incorporation into CS-UbC-RfA-IRES2-hKO1 lentivirus vector supplied by Inst. of Physical and Chemical Research and infecting the iPS cells.

20 [0193]

3. Differentiation of iPS cells with WT1-TCR gene introduced thereinto into CD8-positive T cells (CTL)

Differentiation of iPS cells with WT1-TCR gene introduced thereinto into CD8-positive T cells (CTL) was performed
25 according to a known method (WO 2017/221975). The present cells were CD3-positive, CD8-positive. In the following, the cells were used as iPS cell-derived T cells.

[0194]

4. Reagent, antibody

30 RetroNectin (registered trade mark) was purchased from Takara Bio Inc. As the anti-CD3 agonist antibody, anti-human CD3 functional grade purified (Clone: OKT3) purchased from eBioscience or CD3 antibody (Clone: UCHT1) purchased from GeneTex was used. Unless particularly indicated, OKT3 was used.
35 As the anti-CD30 agonist antibody, CD30 agonist antibody

purchased from R&D systems was used.

[0195]

5. Immobilization of anti-CD3 agonist antibody and RetroNectin (registered trade mark) on culture plate

5 The anti-CD3 agonist antibody and RetroNectin (registered trade mark) dissolved in PBS to necessary concentrations were added to a 96 well plate at 50 μ L/well, and the plate was allowed to stand at 4°C overnight. The cells were washed with PBS and subjected to the test.

10 [0196]

6. ELISA for detection of immobilized anti-CD3 agonist antibody and immobilized RetroNectin (registered trade mark)

For the detection of immobilized anti-CD3 agonist antibody, HRP Conjugated Goat anti-Mouse IgG2a Detection
15 Antibody contained in the Mouse IgG2a ELISA Quantitation Set purchased from Bethyl Laboratories was used. For the detection of immobilized RetroNectin (registered trade mark), peroxidase-labeled anti-RetroNectin antibody contained in the RetroNectin EIA kit purchased from Takara Bio Inc. was used. Each
20 detection antibody was added to a immobilized plate, the plate was allowed to stand for 1 hr at room temperature. After washing with PBS containing 0.05% Tween-20, 1-Step™ Ultra TMB-ELISA Substrate Solution (ThermoFisher) was added. After standing for 15 min at room temperature, 1M sulfuric acid was
25 added to discontinue the reaction, and the absorbance at 450 nm was measured using a plate reader.

[0197]

7. Proliferation test

iPS cell-derived T cells prepared to 100,000 cells/200 μ L
30 in a medium prepared by adding cytokine and the like of Table 1 to α -MEM medium containing 15% FBS were seeded in a plate with an anti-CD3 agonist antibody (3, 30, 300, 3000 ng/ml) and RetroNectin (registered trade mark) (0, 1.85, 2.25, 16.7, 50, 150 μ g/ml) immobilized thereon, and cultured for 3 days under
35 5% CO₂/37°C.

On day 3 of culture, the cells were harvested from the plate, and the number of the cells was measured using TC20 (Bio-Rad). The cells were suspended in an appropriate amount of a medium obtained by adding cytokine and the like in Table 2 to α -MEM medium containing 15% FBS, added to a non-immobilized 96 well plate and cultured at 5% CO₂/37°C. Thereafter, the cells were collected from the plate on any of days 5, 6, 7, 8, 9, 10, 12, 14 and 16 once each timing and 4 to 7 times in total, and the number of cells was measured. The cells were suspended in an appropriate amount, added to a non-immobilized plate and cultured at 5% CO₂/37°C.

[0198]

[Table 1]

product name	manufacturer	Final conc
ITS (100x) (Insulin-Transferrin-Selenium Supplements)	Invitrogen	1 x
Ascorbic acid 2-phosphate	sigma	50 µg/ml
IL-7	Peprotech	10 ng/ml
IL-15	Peprotech	10 ng/ml
IL-2	Peprotech	10 ng/ml
IL-21	Peprotech	20 ng/ml
IL-12	Merck	50 ng/ml
IL-18	MBL	50 ng/ml
Z-VAD-FMK	R&D	10 µM

15 [0199]

[Table 2]

product name	manufacturer	Final conc
ITS (100x) (Insulin-Transferrin-Selenium Supplements)	Invitrogen	1 x
Ascorbic acid 2-phosphate	sigma	50 µg/ml
IL-7	Peprotech	10 ng/ml
IL-15	Peprotech	10 ng/ml

[0200]

8. ATP test

20 The cells on day 12 of culture in the proliferation test

and ATP in the culture supernatant were measured according to the standard protocol and using CellTiter-Glo(R) Luminescent Cell Viability Assay purchased from Promega KK.

[0201]

5 9. Measurement of WT1 antigen-specific cytotoxic activity

HLA-A*24:02-positive LCL cells were purchased from RIKEN BioResource center. The cells were cultured in a RPMI1640 medium containing 10% FBS. Synthesis of WT1 antigen peptide (CMTWNQMNL: SEQ ID NO: 3) was outsourced to Scrum Inc. The
10 cytotoxicity test was evaluated according to the standard protocol and using DELFIA immunoassay purchased from Perkin Elmer Inc.

[0202]

10. Proliferation test with addition of anti-CD30 agonist
15 antibody

An anti-CD30 agonist antibody diluted to a final concentration of 0, 30, 100, 300 ng/mL was added to the culture medium during suspending of the cells. The rest was the same as in the method of "7. Proliferation test".

20 In the proliferation test of iPS cell-derived T cells by multiple stimulations with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody, an anti-CD30 agonist antibody diluted to a final concentration of 100 ng/mL was added to the culture
25 medium during suspending of the cells. The rest was the same as in the method of "7. Proliferation test".

[0203]

11. Detection of CD197 and CD45RA on cell membrane surface

The cells on day 7 of culture were harvested, stained
30 with the antibody of Table 3, and detected using LSRFortessa™ X-20 (BD Bioscience) flow cytometry.

[0204]

[Table 3]

Target	Fluorescent	clone	Vender
CD5	APC/Cy7	UCHT2	BioLegend
CD8a	PerCP/Cy5.5	SK1	BioLegend
CD8b	PE/Cy7	SID18BEE	eBioscience
CD197	AF647	G043H7	BioLegend
CD45RA	FITC	HI100	BioLegend

[0205]

5 [Experimental Example 1]

1. Measurement of concentration of anti-CD3 agonist antibody and concentration of RetroNectin (registered trade mark) suitable for immobilizing on culture plate

The concentration of an anti-CD3 agonist antibody and
10 RetroNectin (registered trade mark) suitable for immobilizing on a culture plate was measured by the ELISA method (Fig. 1). Concentration-dependent immobilizing of an anti-CD3 agonist antibody was confirmed between 3 ng/mL and 3000 ng/mL. Concentration-dependent immobilizing of RetroNectin (registered
15 trade mark) was confirmed between 16.7 µg/mL and 150 µg/mL.

[0206]

2. Verification of concentration range of anti-CD3 agonist antibody and RetroNectin (registered trade mark) necessary for immobilized anti-CD3 agonist antibody and immobilized
20 RetroNectin (registered trade mark) suitable for proliferation of iPS cell-derived T cells

iPS cell-derived T cells were stimulated for 3 days on a plate with an anti-CD3 agonist antibody (0, 3, 30, 300, 3000 ng/mL) and RetroNectin (registered trade mark) (0, 1.85, 5.56,
25 16.7, 50, 150 µg/mL) immobilized thereon, and cultured on a non-immobilized plate for 9 days, and the amount of ATP was measured (Fig. 2).

[0207]

3. Proliferation test of iPS cell-derived T cells stimulated
30 with immobilized anti-CD3 agonist antibody/RetroNectin

(registered trade mark)

iPS cell-derived T cells prepared at 100,000 cells/200 μ L were stimulated for 3 days on a 96 well plate with an anti-CD3 agonist antibody (3000 ng/mL) and RetroNectin (registered trade mark) (150 μ g/mL) immobilized thereon, or with anti-CD3/CD28 beads (Dynabeads) in which the ratio of the number of iPS cell-derived T cells and the number of bead particles is 1:1, and the number of cells cultured without stimulation was measured over time (Fig. 3). The iPS cell-derived T cells were proliferated more by stimulating with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) than with anti-CD3/CD28 beads.

[0208]

4. Proliferation test of iPS cell-derived T cells stimulated multiple times with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark)

The cell proliferation reaction of iPS cell-derived T cells to multiple times of stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) was confirmed. One proliferation test was performed by stimulating iPS cell-derived T cells for 3 days on an immobilized plate and culturing the cells for 11-15 days on a non-immobilized plate. After the completion of the test, the number of cells was adjusted and subjected to the next test. The iPS cell-derived T cells responded to the fourth stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and proliferated (Fig. 4).

[0209]

5. Verification of WT1 antigen-specific cytotoxic activity of WT1-TCR gene-transferred iPS cell-derived T cells proliferated by stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark)

The WT1 antigen-specific cytotoxic activity of WT1-TCR gene-transferred iPS cell-derived T cells proliferated by the stimulation with immobilized anti-CD3 agonist

antibody/RetroNectin (registered trade mark) was evaluated. The WT1 antigen-specific cytotoxic activity was evaluated based on the difference between the cytotoxicity against LCL added with WT1 antigen peptide and the cytotoxicity against LCL free of the addition. The WT1-TCR gene-transferred iPS cell-derived T cells scarcely had non-specific cytotoxic activity and showed WT1 antigen-specific cytotoxic activity alone (Fig. 5).

[0210]

6. Proliferation test of iPS cell-derived T cells by stimulation with anti-CD30 agonist antibody

Whether addition of an anti-CD30 agonist antibody (0, 30, 100, 300 ng/mL) during stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) influences proliferation of iPS cell-derived T cells was verified. As the immobilized 96 well plate, one on which an anti-CD3 agonist antibody (3000 ng/ml) and RetroNectin (registered trade mark) (150 µg/ml) were immobilized was used. iPS cell-derived T cells were proliferated more by the addition of an anti-CD30 agonist antibody. The cells were proliferated in an anti-CD30 agonist antibody concentration dependent manner (Fig. 6).

[0211]

7. Proliferation test of iPS cell-derived T cells by multiple times of stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

Whether iPS cell-derived T cells show a proliferation reaction by multiple times of stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody was verified. The cells were seeded in a plate containing anti-CD3 antibody (3000 ng/ml) and RetroNectin (registered trade mark) (150 µg/ml) immobilized thereon and cultured at 5% CO₂/37°C for 3 days.

On day 3 of culture, the cells were harvested from the plate, and the number of the cells was measured using TC20 (Bio-Rad). The cells were suspended in an appropriate amount

of a medium obtained by adding cytokine and the like in Table 2 to α -MEM medium containing 15% FBS, added to a non-immobilized plate and cultured at 5% CO₂/37°C. Thereafter, the cells were collected from the plate once each on days 6, 7, 9, 10, 14 and 5 16, and the number of cells was measured. The cells were suspended in an appropriate amount, added to a non-immobilized plate and cultured at 5% CO₂/37°C. As the culture medium, one added with an anti-CD30 agonist antibody diluted to the final concentration of 100 ng/mL, and one free of an anti-CD30 10 agonist antibody were used. The above-mentioned stimulation from day 0 to day 16 of culture was repeated twice. Even by the second stimulation, the iPS cell-derived T cells were proliferated by the stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti- 15 CD30 agonist antibody as compared to the stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) alone (Fig. 7).

[0212]

8. Detection of CD197 and CD45RA on membrane surface of iPS 20 cell-derived T cell after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

After stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark), or stimulation 25 with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody, the expression of CD197 and CD45RA on the membrane surface of iPS cell-derived T cells on day 7 was measured by flow cytometer. In the cell population stimulated with anti-CD3 agonist 30 antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody, CD197-positive CD45RA-negative central memory-like iPS cell-derived T cells were in the majority (Fig. 8).

[0213]

35 9. Verification of WT1 antigen-specific cytotoxic activity of

WT1-TCR gene-transferred iPS cell-derived T cells proliferated by stimulation with immobilized anti-CD3 agonist antibody/RetroNectin and anti-CD30 agonist antibody

WT1-TCR gene-transferred iPS cell-derived T cells
5 proliferated by the stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody were applied to HLA-A*24:02-positive LCL cells in the presence or absence of WT1 antigen peptide, and the WT1 antigen-specific cytotoxic activity was evaluated. The
10 WT1-TCR gene-transferred iPS cell-derived T cells scarcely had non-specific cytotoxic activity and showed WT1 antigen-specific cytotoxic activity alone (Fig. 9).

[0214]

[Example 2]

15 1. Preparation of human peripheral blood-derived CD8-positive T cells

Human peripheral blood was healthy donor-derived peripheral blood mononuclear cell purchased from Precision Bioservices. Using CD8+ T cell isolation kit, human (Milteny),
20 CD8-positive T cells were isolated.

[0215]

2. Proliferation test of human peripheral blood-derived CD8-positive T cells

By a method similar to that in [Example 1] 7.
25 Proliferation test, the test was conducted.

[0216]

3. Culture of human peripheral blood-derived CD8-positive T cells used for mouse engraftment test

To human peripheral blood-derived CD8-positive T cells
30 suspended at a final concentration of 100,000 cells/mL in 3 kinds of media obtained by adding additives shown in Table 4 to α -MEM medium containing 15% FBS was added Dynabeads T-Activator CD3/CD28 (gibco) adjusted to a 3-fold amount of the number of cells, and the cells were cultured at 5% CO₂/37°C for 3 days.
35 The cells were harvested from the plate on day 3 of culture and

suspended in an appropriate amount of a medium obtained by adding cytokine and the like shown in Table 5 to α -MEM medium containing 15% FBS, and cultured at 5% CO₂/37°C. Thereafter, the cells were collected from the plate on day 10 of culture, and the number of cells was measured. The cells were suspended in an appropriate amount and administered to the mice. On days 6, 10, 13, 17 of culture, the cells were collected from the plate, suspended in an appropriate amount, and subjected to a CD197 expression experiment.

10 [0217]

[Table 4]

product name	manufacturer	Final conc	w IL2	w IL7/ IL15	w IL7/IL15/ anti-CD30Ab
Insulin- Transferrin- Selenium Supplements	Invitrogen	1 x	+	+	+
Ascorbic acid 2-phosphate	sigma	50 µg/ml	+	+	+
IL-2	Peprotech	15 ng/ml	+		
IL-7	Peprotech	10 ng/ml		+	+
IL-15	Peprotech	10 ng/ml		+	+
IL-21	Peprotech	20 ng/ml		+	+
IL-12	Merck	50 ng/ml		+	+
IL-18	MBL	50 ng/ml		+	+
TL-1A	Peprotech	50 ng/ml		+	+
Z-VAD-FMK	R&D	10 µM		+	+
Human CD30 Antibody	R&D	300 ng/ml			+

w: with (additive added to each group is shown with +.)

[0218]

[Table 5]

product name	manufacturer	Final conc	w IL2	w IL7/ IL15	w IL7/IL15/ anti-CD30Ab
Insulin- Transferrin- Selenium Supplements	Invitrogen	1 x	+	+	+
Ascorbic acid 2-phosphate	sigma	50 µg/ml	+	+	+
IL-2	Peprotech	15 ng/ml	+		
IL-7	Peprotech	10 ng/ml		+	+
IL-15	Peprotech	10 ng/ml		+	+
Human CD30 Antibody	R&D	300 ng/ml			+

w: with (additive added to each group is shown with +.)

5 [0219]

4. Administration of human peripheral blood-derived CD8-positive T cells to mouse and recovery of cells engrafted cells

8-week-old male NSG mouse (Japan Charles River), which was irradiated with 2 Gy of gamma rays before the cell

10 administration on the same day, was used. 5,000,000 cells adjusted in Culture of human peripheral blood-derived CD8-positive T cells used for mouse engraftment test in [Example 2]

3. were intravenously administered to mice, and the mice were bred for 4 weeks. Thereafter, the mice were euthanized and

15 bone marrow cells, splenocytes, and leukocytes in the blood were collected from the mice.

[0220]

5. Detection of human peripheral blood-derived CD8-positive T cells engrafted into mouse tissue

20 The collected cells were stained with the antibody of Table 3, and detected using LSRFortessa™ X-20 (BD Bioscience) flow cytometry.

[0221]

[Experimental Example 2]

1. Proliferation test of human peripheral blood-derived CD8-positive T cells by stimulation with anti-CD30 agonist antibody

Whether addition of an anti-CD30 agonist antibody during stimulation with immobilized anti-CD3 antibody/RetroNectin (registered trade mark) influences proliferation of human peripheral blood-derived CD8-positive T cells was confirmed. Addition of the anti-CD30 agonist antibody promoted proliferation of CD8-positive T cells in human peripheral blood (Fig. 10).

10 [0222]

2. Detection of CD197 on membrane surface of human peripheral blood-derived CD8-positive T cell after stimulation with anti-CD3/CD28 bead and anti-CD30 agonist antibody

CD197 expression on the cell membrane surface of human peripheral blood-derived CD8-positive T cells stimulated with anti-CD3/CD28 beads in IL-2-containing medium or IL-7/IL-15-containing medium, IL-7/IL-15/anti-CD30 antibody-containing medium on days 6, 10, 13, 17 of culture was measured by flow cytometer. On day 6, CD197 expression was confirmed in all groups. However, CD197 expression almost disappeared on day 13 in the IL-2-containing medium group and on day 17 in the IL-7/IL-15-containing medium group, whereas CD197 expression was maintained even on day 17 in the IL-7/IL-15/anti-CD30 antibody-containing medium group (Fig. 11).

25 [0223]

3. Evaluation of engraftment of human peripheral blood-derived CD8-positive T cells after stimulation with anti-CD3/CD28 bead and anti-CD30 agonist antibody

Human peripheral blood-derived CD8-positive T cells stimulated with anti-CD3/CD28 beads in IL-2-containing medium or IL-7/IL-15-containing medium, IL-7/IL-15/anti-CD30 antibody-containing medium on day 10 of culture were intravenously administered to immunodeficient mice, and engraftment in blood and immune tissues was confirmed. On day 28 after administration, blood, spleen and bone marrow were collected

from the mice, and human CD8-positive T cells contained therein were detected by flow cytometry. Almost no human CD8-positive T cells were detected in the IL-2-containing medium group in any of the organs, whereas human CD8-positive T cells were
5 detected in the IL-7/IL-15-containing medium group and IL-7/IL-15/anti-CD30 antibody containing medium group. In the IL-7/IL-15/anti-CD30 antibody-containing medium group, a larger number of human CD8-positive T cells were detected. Therefore, it was shown that human peripheral blood-derived CD8-positive T cells
10 cultured in a medium containing IL-7/IL-15/anti-CD30 antibody can not only maintain the expression of CD197 for a long time during culture, but also can survive for a long time in vivo (Fig. 12).

[0224]

15 [Example 3]

1. Proliferation test of iPS cell-derived anti-CD19-CART cells
iPS cell-derived anti-CD19-CART cells prepared to 100,000 cells/200 μ L in a medium prepared by adding cytokine and the like of Table 1 to α -MEM medium containing 15% FBS were seeded
20 in a plate containing anti-CD3 antibody and RetroNectin immobilized thereon and cultured at 5% CO₂/37°C for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using TC20 (Bio-Rad). The cells were suspended in an appropriate amount of a medium
25 obtained by adding cytokine and the like shown in Table 2 to α -MEM medium containing 15% FBS, added to a non-immobilized plate and cultured at 5% CO₂/37°C. Thereafter, the cells were collected from the plate 4 to 7 times on any of days 5, 6, 7, 8, 9, 10, 12, 14, 16 of culture, and the number of cells was
30 measured. The cells were suspended in an appropriate amount, added to a non-immobilized plate and cultured at 5% CO₂/37°C.

[0225]

2. Anti-CD19-CAR gene

As an anti-CD19-CAR gene, an oligo DNA encoding a
35 polypeptide (SEQ ID NO: 5) designed to align in the order shown

in Table 6 from the N-terminal was artificially synthesized.

[0226]

[Table 6]

order from N-terminal	gene	amino acid number
1	lead sequence of immunoglobulin heavy chain	22
2	variable region of anti-CD19 antibody (FMC60) light chain	104
3	GGGGS linker	15
4	variable region of anti-CD19 antibody (FMC60) heavy chain	120
5	CD8-derived sequence (including transmembrane region)	83
6	intracellular domain region of CD28	41
7	intracellular domain region of 4-1BB	47
8	intracellular domain region of CD3ζ	112

5 [0227]

3. Production of retrovirus vector carrying anti-CD19-CAR gene

The artificial oligo DNA synthesized in [Example 3] 2. was incorporated into the multicloning site of pMEI-5 retrovirus vector. The production of the virus vector was
10 outsourced to Unitech.

[0228]

4. Production of iPS cell-derived anti-CD19-CART cells

The iPS cell-derived T cells produced in [Example 1] 3. were infected with the retrovirus vector carrying an anti-CD19-
15 CAR gene and produced in [Example 3] 3., whereby iPS cell-derived anti-CD19-CART cells was produced.

[0229]

[Experimental Example 3]

1. Proliferation test of iPS cell-derived anti-CD19-CART cells
20 stimulated with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark)

The iPS cell-derived T cells produced in [Example 1] 3.

and the iPS cell-derived anti-CD19-CART cells produced in [Example 3] 4. were stimulated for 3 days with immobilized anti-CD3 antibody/RetroNectin (registered trade mark), and the number of cells cultured without stimulation was measured over
5 time. The iPS cell-derived anti-CD19-CART cells were proliferated to the same level as iPS cell-derived T cells by the stimulation with immobilized anti-CD3 antibody/RetroNectin (registered trade mark) (Fig. 13).

[0230]

10 2. Proliferation test of iPS cell-derived anti-CD19-CART cells by stimulation with anti-CD30 agonist antibody

Whether addition of an anti-CD30 agonist antibody during stimulation with immobilized anti-CD3 antibody/RetroNectin (registered trade mark) influences proliferation of iPS cell-
15 derived anti-CD19-CART cells was confirmed. Addition of the anti-CD30 agonist antibody promoted proliferation of iPS cell-derived anti-CD19-CART cells (Fig. 14).

[0231]

3. Detection of CD197 on membrane surface of iPS cell-derived
20 anti-CD19-CART cell after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

CD197 expression on the cell membrane surface of iPS cell-derived anti-CD19-CART cells on days 3 and 7 after
25 stimulation with immobilized anti-CD3 antibody/RetroNectin (registered trade mark), or after stimulation with immobilized anti-CD3 antibody/RetroNectin (registered trade mark)/anti-CD30 agonist antibody was measured by flow cytometer. On day 3, CD197 expression was confirmed in both groups. However, CD197
30 expression almost disappeared on day 7 in the anti-CD3 antibody/RetroNectin (registered trade mark) stimulation group, but it was confirmed that the CD197 expression was maintained in the anti-CD3 antibody/RetroNectin (registered trade mark)+anti-CD30 agonist antibody stimulation group (Fig. 15).

35 [0232]

4. Verification of Raji cytotoxic activity of iPS cell-derived anti-CD19-CART cell after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

5 The cytotoxic activity of iPS cell-derived anti-CD19-CART cells obtained by proliferation in [Experimental Example 3] 1. against CD19-positive cancer cells was evaluated by the cytotoxic activity against CD19-positive Raji cells. The iPS cell-derived anti-CD19-CART cells showed cytotoxic activity
10 against CD19-expressing Raji cells (Fig. 16).

[0233]

[Example 4]

1. Anti-CD19-CAR gene containing CD30-derived intracellular domain

15 As anti-CD19-CAR gene, an oligo DNA encoding a polypeptide (SEQ ID NO: 7) designed to align in the order shown in Table 7 from the N-terminal was artificially synthesized.

[0234]

[Table 7]

order from N-terminal	gene	amino acid number
1	lead sequence of immunoglobulin heavy chain	22
2	variable region of anti-CD19 antibody (FMC60) light chain	104
3	GGGS linker	15
4	variable region of anti-CD19 antibody (FMC60) heavy chain	120
5	CD8-derived sequence (including transmembrane region)	83
6	intracellular domain region of CD28	41
7	intracellular domain region of CD30 (SEQ ID NO: 6)	87
8	intracellular domain region of CD3ζ	112

20

[0235]

2. Production of retrovirus vector carrying anti-CD19-CAR gene

containing CD30-derived intracellular domain

The artificial oligo DNA synthesized in [Example 4] 1. was incorporated into the multicloning site of pMY retrovirus vector. Using FLYRD18 cells for retrovirus vector production,
5 a virus vector was produced.

[0236]

3. Production of iPS cell-derived anti-CD19-CART cells (iCD19-CD30-CART) containing CD30-derived intracellular domain

The iPS cell-derived T cells produced in [Example 1]3.
10 were infected with the retrovirus vector carrying an anti-CD19-CAR gene and produced in [Example 4] 2., whereby iPS cell-derived anti-CD19-CART cells (iCD19-CD30-CART) containing a CD30-derived intracellular domain were produced.

[0237]

15 [Experimental Example 4]

The cytotoxic activity of iCD19-CD30-CART obtained in [Example 4] 3. against CD19-positive cancer cells was evaluated by the cytotoxic activity against CD19-positive Raji cells. The iCD19-CD30-CART showed cytotoxic activity against CD19-
20 expressing Raji cells (Fig. 17).

[0238]

[Example 5]

1. Preparation of iPS cell

Similar to [Example 1], as the iPS cell, Ff-I01s04 strain
25 provided by the Center for iPS Cell Research and Application (CiRA), Kyoto University, was used. iPS cell culture was performed according to the protocol distributed by CiRA, "Human iPS cell culture under feeder-free conditions".

[0239]

30 2. Differentiation of iPS cells into $\gamma\delta$ TCR-positive T cells ($\gamma\delta$ T cells)

Differentiation of iPS cells into $\gamma\delta$ TCR-positive T cells ($\gamma\delta$ T cells) was performed according to a known method (WO 2017/221975) as in [Example 1]. As the anti-CD3 antibody used
35 in the differentiation step, 3000 ng/mL UCHT1 (manufactured by

GeneTex) was used. The obtained CD3-positive cells were $\gamma\delta$ T cells (hereinafter to be referred to as "iPS cell-derived $\gamma\delta$ T cells (i $\gamma\delta$ T cells)").

[0240]

5 3. Expansion culture of iPS cell-derived $\gamma\delta$ T cells

The i $\gamma\delta$ T cells obtained in [Example 5] 2. were suspended at 2,000,000 cells/mL in a medium obtained by adding cytokine shown in Table 8 to α -MEM medium containing 15% FBS, and the suspension was seeded in a plate containing anti-CD3 antibody
10 (UCHT1) and RetroNectin (registered trade mark) immobilized thereon and cultured at 5% CO₂/37°C for 3 days. The cells were harvested from the plate on day 3 of culture and the number of the cells was measured using NucleoCounter NC-200 (ChemoMetec). The cells were suspended in an appropriate amount of a medium
15 obtained by adding cytokine and the like shown in Table 9 to α -MEM medium containing 15% FBS, added to a non-immobilized G-Rex 6-well plate (WILSONWOLF) and cultured at 5%CO₂/37°C. Thereafter, a part of the cells were collected from the plate 4 to 6 times on any of days 5, 6, 7, 8, 9, 10, 11, 14, 17 of
20 culture, and the number of cells was measured. The cells were immobilized on the culture plate with anti-CD3 antibody and RetroNectin (registered trade mark) by the following method. An anti-CD3 antibody (UCHT1, final concentration 3000 ng/mL) and RetroNectin (final concentration 150 μ g/mL) dissolved in
25 PBS at necessary concentrations were added to the plate and the plate was stood overnight at 4°C. The plate was washed with PBS and subjected to the test.

[0241]

[Table 8]

product name	manufacturer	Final conc	w/ anti-CD30 Ab	w/o anti-CD30 Ab
Insulin-Transferrin-Selenium Supplements	Invitrogen	1 x	+	+
Ascorbic acid 2-phosphate	sigma	50 µg/ml	+	+
IL-2	Peprotech	15 ng/ml	+	+
IL-7	Peprotech	10 ng/ml	+	+
IL-15	Peprotech	10 ng/ml	+	+
IL-21	Peprotech	20 ng/ml	+	+
IL-12	Merck	50 ng/ml	+	+
IL-18	MBL	50 ng/ml	+	+
TL-1A	Peprotech	50 ng/ml	+	+
Z-VAD-FMK	R&D	10 µM	+	+
Human CD30 Antibody	R&D	300 ng/ml		+

w/: with, w/o without

Additive added to each group is shown with "+".

5 [0242]

[Table 9]

product name	manufacturer	Final conc	w/ anti-CD30 Ab	w/o anti-CD30 Ab
Insulin-Transferrin-Selenium Supplements	Invitrogen	1 x	+	+
Ascorbic acid 2-phosphate	sigma	50 µg/ml	+	+
IL-2	Peprotech	15 ng/ml	+	+
IL-7	Peprotech	10 ng/ml	+	+
IL-15	Peprotech	10 ng/ml	+	+
Human CD30 Antibody	R&D	300 ng/ml	+	+

w/: with, w/o without

Additive added to each group is shown with "+".

10 [0243]

[Experimental Example 5]

1. Proliferation test of iPS cell-derived $\gamma\delta$ T cells by stimulation with anti-CD30 agonist antibody

Whether addition of an anti-CD30 agonist antibody (300 ng/mL) to the stimulation method using immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) in [Example 5] 3. influences proliferation of iPS cell-derived $\gamma\delta$ T cells was verified. iPS cell-derived T cells were proliferated by the addition of an anti-CD30 agonist antibody (Fig. 18).
[0244]

10 [Example 6]

1. IL-15R α /IL-15 gene

As IL-15R α /IL-15 gene, an oligo DNA encoding a polypeptide (SEQ ID NO: 8) designed to align in the order shown in Table 10 from the N-terminal was artificially synthesized.

15 [0245]

[Table 10]

order from N-terminal	gene	amino acid number
1	lead sequence of human IL-2	23
2	C-terminal sequence of human IL-15	114
3	GGGS linker	24
4	C-terminal sequence of human IL-15RA	239

[0246]

2. Production of retrovirus vector carrying IL-15R α /IL-15 gene

20 The artificial oligo DNA synthesized in [Example 6] 1. was incorporated into the multicloning site of pMY retrovirus vector. Using FLYRD18 cells for retrovirus vector production, a virus vector was produced.

[0247]

25 3. Production of iPS cell-derived anti-CD19-CAR/IL-15 $\gamma\delta$ T cells

The iPS cell-derived $\gamma\delta$ T cells (i $\gamma\delta$ T cells) produced in [Example 5] 2. were infected with the retrovirus vector carrying anti-CD19-CAR gene and produced in [Example 3] 3. and the retrovirus vector carrying IL-15R α /IL-15 gene and produced in [Example 6] 1., whereby iPS cell-derived anti-CD19-CAR/IL-

15 γ δ T cells (iCD19CAR/IL-15 γ δ T cells) were produced.

[0248]

4. Expansion culture of iPS cell-derived anti-CD19-CAR/IL-15 γ δ T cells

- 5 By a method similar to that in [Example 5]3., expansion culture of iCD19CAR/IL-15 γ δ T cells was performed except that IL-2 was not added.

[0249]

[Experimental Example 6]

- 10 1. Proliferation test of iPS cell-derived anti-CD19-CAR/IL-15 γ δ T cells by stimulation with anti-CD30 agonist antibody

Whether addition of an anti-CD30 agonist antibody (0, 30, 100, 300 ng/mL) during stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) in

- 15 [Example 6] 4. influences proliferation of iCD19CAR/IL-15 γ δ T cells was verified. The cells were proliferated more by the addition of an anti-CD30 agonist antibody (Fig. 19).

[0250]

2. Study of cytotoxic activity of iPS cell-derived anti-CD19-
20 CAR/IL-15 γ δ T cell after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

- The cytotoxic activity of iCD19CAR/IL-15 γ δ T cells obtained in [Example 6] 4., was evaluated. Using CD19-positive
25 Raji cell and CD19 negative CCRF-CEN cell as target cells, iCD19CAR/IL-15 γ δ T cells were mixed at a proportion of 0.5, 1, 2, 4, 8, 16-fold relative to the target cell. The cytotoxic activity of iCD19CAR/IL-15 γ δ T cells was evaluated based on the target cell death 2 hr later. It was shown that iCD19CAR/IL-
30 15 γ δ T cells expansion cultured in a medium containing an anti-CD30 agonist antibody has cytotoxic activity against CD19-positive Raji cell, does not have cytotoxic activity against CD19-negative CCRF-CEN cells (Fig. 20).

[0251]

- 35 3. Number of survival day-increasing effect of iPS cell-derived

anti-CD19-CAR/IL-15 γ δ T cells after stimulation with immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark) and anti-CD30 agonist antibody

5 5×10^5 Nalm6 cells (ATCC) were transplanted to NOD/Shi-scid, IL-2R γ KO (NOG) mice (Central Institute for Experimental Animals, female, 7-8-week-old) from the tail vein to prepare Nalm6 xenograft mice. On day 4 post-transplantation, a suspension of iCD19CAR/IL-15 γ δ T cells (5×10^6 (cells)) obtained in [Example 6] 4. in 0.1 mL of HBSS-buffer or an equal amount
10 of HBSS-buffer was administered from the tail vein, and the number of days of survival was confirmed. All mice transplanted with CD19-positive Nalm6 cancer cells via the tail vein died within 3 weeks in the control administration group, whereas all mice survived for at least 6 weeks in the
15 iCD19CAR/IL-15 γ δ T cell administration group expansion cultured in a medium containing an anti-CD30 agonist antibody (Fig. 21).
[0252]

[Example 7]

1. Production of iPS cell-derived anti-CD19-CAR/IL-15 α β T cells
20 iPS cell-derived anti-CD19-CART cells produced by the method of [Example 3] 4. were infected with the retrovirus vector carrying IL15R α /IL-15 gene of the produced in [Example 6] 2. to produce iPS cell-derived anti-CD19-CAR/IL-15 α β T cells (iCD19CAR/IL-15 α β T cells).

25 [0253]

2. Expansion culture of iCD19CAR/IL-15 α β T cells by using immobilized anti-CD3 agonist antibody/RetroNectin (registered trade mark)

The iCD19CAR/IL-15 α β T cells obtained in [Example 7] 1.
30 were cultured by a method similar to that in [Example 6] 4. until day 7. An anti-human CD30 antibody was not added.

[0254]

[Experimental Example 7]

1. In vivo antitumor effect of iCD19CAR/IL-15 α β T cells after
35 stimulation with immobilized anti-CD3 agonist

antibody/RetroNectin (registered trade mark)

5x10⁵ luciferase-expressing Nalm6 cells (ATCC) were transplanted to NOD/Shi-scid, IL-2RyKO (NOG) mice (Central Institute for Experimental Animals, female, 7-8-week-old) from the tail vein to prepare luciferase-expressing Nalm6 xenograft mice. On day 4 post-transplantation, a suspension of iCD19CAR/IL-15αβT cells (5x10⁶ cells) obtained in [Example 7] 2. in 0.1 mL of HBSS-buffer or an equal amount of HBSS-buffer was administered from the tail vein. Luciferin was administered from the tail vein every week after administration, and the activity of luciferase expressed by Nalm6 cells was measured using IVIS. In the control-administered group, luminescence derived from Nalm6 cells was confirmed throughout the body 2 weeks after administration, and all mice died by 3 weeks after administration, whereas no luminescence was detected until 6 weeks after administration in the iCD19CAR/IL-15αβT cell-administered group (Fig. 22).

[0255]

[Example 8]

1. Production of iPS cell-derived γδT cells

In the same manner as in [Example 5] 1. and 2., iPS cell-derived γδT cells (iγδT cells) were produced.

[0256]

[Experimental Example 8]

1. Measurement of concentration of anti-CD3 agonist antibody (UCHT1) suitable for immobilization on culture plate and concentration of RetroNectin (registered trade mark)

An anti-CD3 agonist antibody (UCHT1) and RetroNectin (registered trade mark) were mixed and immobilized on a culture plate in the same manner as in [Example 1] 5. Thereafter, the amount thereof immobilized on a culture plate was measured using the ELISA method (Fig. 23). Concentration-dependent immobilization of an anti-CD3 agonist antibody free of mixing with RetroNectin (registered trade mark) was confirmed between 3 ng/mL and 3000 ng/mL (0.003 μg/ml to 30 μg/ml). However, the

amount of immobilized anti-CD3 agonist antibody decreased as the concentration of RetroNectin (registered trade mark) to be mixed was raised. On the other hand, concentration-dependent immobilization of RetroNectin (registered trade mark) was confirmed between 16.7 µg/mL and 150 µg/mL.

[0257]

2. Verification of concentration range of anti-CD3 agonist antibody and RetroNectin (registered trade mark) necessary for immobilized anti-CD3 agonist antibody and immobilized RetroNectin (registered trade mark) suitable for proliferation of iPS cell-derived iγδT cells

iγδT cells adjusted to 100,000 cells/200 µL in a medium obtained by adding cytokine and the like of Table 1, and anti-CD30 agonist antibody diluted to a final concentration of 0, 3, 30, 300 ng/ml to IMDM medium containing 15% FBS were seeded in a plate with an anti-CD3 agonist antibody (0, 300, 3000, 30000 ng/ml (0, 0.3, 3, 30 µg/ml)) and RetroNectin (registered trade mark) (0, 2, 15, 150 µg/mL) immobilized thereon, and cultured for 3 days under 5% CO₂/37°C.

On day 3 of culture, the cells were harvested from the plate, suspended in an appropriate amount of a medium obtained by adding cytokine and the like in Table 2 to IMDM medium containing 15% FBS, seeded in a non-immobilized 96 well plate and cultured at 5% CO₂/37°C. Thereafter, the cells were collected from the plate on any of days 5, 6, 7, 8, 9, 10, and 12 once each timing and 4 to 7 times in total, suspended in an appropriate amount of a medium, seeded in a non-immobilized plate and cultured at 5% CO₂/37°C. On day 13 of culture, the cells were counted using a hemocytometer, and the proliferation rate based on the comparison with the number on day 0 of culture was measured (Fig. 24). Equivalent induction of iγδT cell proliferation was observed in the plates on which a mixture of anti-CD3 agonist antibody and RetroNectin (registered trade mark) was immobilized at 0.3 µg/mL and 2 µg/mL, 3 µg/mL and 15 µg/mL, 30 µg/mL and 150 µg/mL,

respectively. Also, anti-CD30 agonist antibody addition concentration-dependent cell proliferation was confirmed.

[Industrial Applicability]

[0258]

5 T cells can be efficiently expansion cultured repeatedly by culturing CD3-positive cells in the presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist. When the CD3-positive cells to be cultured are CD3-positive CD8-positive cell or CD3-positive CD8-positive CD30-
10 positive cells, the produced or expansion cultured cell easily shift to effector T cells and exhibit cytotoxic activity. Therefore, it can be applied to T cell therapy.

This application is based on patent application No. 2018-151580 filed in Japan (filing date: August 10, 2018), No. 2019-
15 042666 (filing date: March 8, 2019) and No. 2019-117878 (filing date: June 25, 2019), the contents of which are incorporated in full herein.

SEQUENCE LISTING

<110> KYOTO UNIVERSITY
 TAKEDA PHARMACEUTICAL COMPANY LIMITED
 <120> A method of producing CD3-positive cells
 <130> 092932
 <150> JP 2018-151580
 <151> 2018-08-10
 <150> JP 2019-042666
 <151> 2019-03-08
 <150> JP 2019-117878
 <151> 2019-06-25
 <160> 24
 <170> PatentIn version 3.5
 <210> 1
 <211> 9
 <212> PRT
 <213> Homo sapiens
 <400> 1

Arg Met Phe Pro Asn Ala Pro Tyr Leu
 1 5

<210> 2
 <211> 9
 <212> PRT
 <213> Homo sapiens
 <400> 2

Ser Leu Gly Glu Gln Gln Tyr Ser Val
 1 5

<210> 3
 <211> 9
 <212> PRT
 <213> Homo sapiens
 <400> 3

Cys Met Thr Trp Asn Gln Met Asn Leu
 1 5

<210> 4
 <211> 9
 <212> PRT

<213> Homo sapiens

<400> 4

Cys Tyr Thr Trp Asn Gln Met Asn Leu
1 5

<210> 5

<211> 544

<212> PRT

<213> Artificial Sequence

<220>

<223> CD19-CAR

<400> 5

Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1 5 10 15

Ala His Ser Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala
20 25 30

Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile
35 40 45

Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys
50 55 60

Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg
65 70 75 80

Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn
85 90 95

Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr
100 105 110

Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly
115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys
130 135 140

Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser
145 150 155 160

Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Asp Tyr Gly Val Ser
165 170 175

Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly Val Ile
180 185 190

Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser Arg Leu
195 200 205

Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys Met Asn
210 215 220

Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys His Tyr
225 230 235 240

Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
245 250 255

Val Thr Val Ser Ser Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr
260 265 270

Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser
275 280 285

Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly
290 295 300

Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp
305 310 315 320

Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile
325 330 335

Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser Arg Leu Leu
340 345 350

His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg
355 360 365

Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg
370 375 380

Ser Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile
385 390 395 400

Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp
405 410 415

Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu
420 425 430

Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly
435 440 445

Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr
450 455 460

Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys
465 470 475 480

Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys
485 490 495

Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg
500 505 510

Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala
515 520 525

Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
530 535 540

<210> 6
<211> 87
<212> PRT
<213> Homo sapiens

<400> 6

His Thr Asn Asn Lys Ile Glu Lys Ile Tyr Ile Met Lys Ala Asp Thr
1 5 10 15

Val Ile Val Gly Thr Val Lys Ala Glu Leu Pro Glu Gly Arg Gly Leu
20 25 30

Ala Gly Pro Ala Glu Pro Glu Leu Glu Glu Glu Leu Glu Ala Asp His
35 40 45

Thr Pro His Tyr Pro Glu Gln Glu Thr Glu Pro Pro Leu Gly Ser Cys

50

55

60

Ser Asp Val Met Leu Ser Val Glu Glu Glu Gly Lys Glu Asp Pro Leu
65 70 75 80

Pro Thr Ala Ala Ser Gly Lys
85

<210> 7

<211> 965

<212> PRT

<213> Artificial Sequence

<220>

<223> CD19-CAR (CD8-CD28-CD30-CD3z)

<400> 7

Met Asp Trp Thr Trp Arg Ile Leu Phe Leu Val Ala Ala Ala Thr Gly
1 5 10 15

Ala His Ser Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala
20 25 30

Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile
35 40 45

Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys
50 55 60

Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg
65 70 75 80

Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn
85 90 95

Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr
100 105 110

Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr Gly Gly
115 120 125

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val Lys
130 135 140

Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser Leu Ser

145		150		155		160
Val Thr Cys Thr	Val Ser Gly Val Ser	Leu Pro Asp Tyr Gly	Val Ser			
	165	170	175			
Trp Ile Arg Gln Pro Pro Arg Lys	Gly Leu Glu Trp Leu Gly	Val Ile				
	180	185	190			
Trp Gly Ser Glu Thr Thr Tyr Tyr	Asn Ser Ala Leu Lys	Ser Arg Leu				
	195	200	205			
Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val	Phe Leu Lys Met Asn					
	210	215	220			
Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr	Cys Ala Lys His Tyr					
	225	230	235			240
Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr	Trp Gly Gln Gly Thr Ser					
	245	250	255			
Val Thr Val Ser Ser Phe Val Pro Val Phe Leu Pro Ala	Lys Pro Thr					
	260	265	270			
Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro	Thr Ile Ala Ser					
	275	280	285			
Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg	Pro Ala Ala Gly Gly					
	290	295	300			
Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys	Asp Ile Tyr Ile Trp					
	305	310	315			320
Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser	Leu Val Ile					
	325	330	335			
Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys Arg Ser	Arg Leu Leu					
	340	345	350			
His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro	Gly Pro Thr Arg					
	355	360	365			
Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp	Phe Ala Ala Tyr Arg					
	370	375	380			

Ser His Thr Asn Asn Lys Ile Glu Lys Ile Tyr Ile Met Lys Ala Asp
385 390 395 400

Thr Val Ile Val Gly Thr Val Lys Ala Glu Leu Pro Glu Gly Arg Gly
405 410 415

Leu Ala Gly Pro Ala Glu Pro Glu Leu Glu Glu Glu Leu Glu Ala Asp
420 425 430

His Thr Pro His Tyr Pro Glu Gln Glu Thr Glu Pro Pro Leu Gly Ser
435 440 445

Cys Ser Asp Val Met Leu Ser Val Glu Glu Glu Gly Lys Glu Asp Pro
450 455 460

Leu Pro Thr Ala Ala Ser Gly Lys Arg Val Lys Phe Ser Arg Ser Ala
465 470 475 480

Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu
485 490 495

Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly
500 505 510

Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu
515 520 525

Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser
530 535 540

Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly
545 550 555 560

Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu
565 570 575

His Met Gln Ala Leu Pro Pro Arg Leu Glu Gly Gly Gly Glu Gly Arg
580 585 590

Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Arg
595 600 605

Met Leu Leu Leu Val Thr Ser Leu Leu Leu Cys Glu Leu Pro His Pro

610

615

620

Ala Phe Leu Leu Ile Pro Arg Lys Val Cys Asn Gly Ile Gly Ile Gly
 625 630 635 640

Glu Phe Lys Asp Ser Leu Ser Ile Asn Ala Thr Asn Ile Lys His Phe
 645 650 655

Lys Asn Cys Thr Ser Ile Ser Gly Asp Leu His Ile Leu Pro Val Ala
 660 665 670

Phe Arg Gly Asp Ser Phe Thr His Thr Pro Pro Leu Asp Pro Gln Glu
 675 680 685

Leu Asp Ile Leu Lys Thr Val Lys Glu Ile Thr Gly Phe Leu Leu Ile
 690 695 700

Gln Ala Trp Pro Glu Asn Arg Thr Asp Leu His Ala Phe Glu Asn Leu
 705 710 715 720

Glu Ile Ile Arg Gly Arg Thr Lys Gln His Gly Gln Phe Ser Leu Ala
 725 730 735

Val Val Ser Leu Asn Ile Thr Ser Leu Gly Leu Arg Ser Leu Lys Glu
 740 745 750

Ile Ser Asp Gly Asp Val Ile Ile Ser Gly Asn Lys Asn Leu Cys Tyr
 755 760 765

Ala Asn Thr Ile Asn Trp Lys Lys Leu Phe Gly Thr Ser Gly Gln Lys
 770 775 780

Thr Lys Ile Ile Ser Asn Arg Gly Glu Asn Ser Cys Lys Ala Thr Gly
 785 790 795 800

Gln Val Cys His Ala Leu Cys Ser Pro Glu Gly Cys Trp Gly Pro Glu
 805 810 815

Pro Arg Asp Cys Val Ser Cys Arg Asn Val Ser Arg Gly Arg Glu Cys
 820 825 830

Val Asp Lys Cys Asn Leu Leu Glu Gly Glu Pro Arg Glu Phe Val Glu
 835 840 845

Asn Ser Glu Cys Ile Gln Cys His Pro Glu Cys Leu Pro Gln Ala Met
850 855 860

Asn Ile Thr Cys Thr Gly Arg Gly Pro Asp Asn Cys Ile Gln Cys Ala
865 870 875 880

His Tyr Ile Asp Gly Pro His Cys Val Lys Thr Cys Pro Ala Gly Val
885 890 895

Met Gly Glu Asn Asn Thr Leu Val Trp Lys Tyr Ala Asp Ala Gly His
900 905 910

Val Cys His Leu Cys His Pro Asn Cys Thr Tyr Gly Cys Thr Gly Pro
915 920 925

Gly Leu Glu Gly Cys Pro Thr Asn Gly Pro Lys Ile Pro Ser Ile Ala
930 935 940

Thr Gly Met Val Gly Ala Leu Leu Leu Leu Leu Val Val Ala Leu Gly
945 950 955 960

Ile Gly Leu Phe Met
965

<210> 8
<211> 400
<212> PRT
<213> Homo sapiens

<400> 8

Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu
1 5 10 15

Val Thr Asn Ser Ala Thr Ser Asn Trp Val Asn Val Ile Ser Asp Leu
20 25 30

Lys Lys Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr Leu
35 40 45

Tyr Thr Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met Lys
50 55 60

Cys Phe Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp Ala
65 70 75 80

Ser Ile His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser
85 90 95

Leu Ser Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys Glu
100 105 110

Glu Leu Glu Glu Lys Asn Ile Lys Glu Phe Leu Gln Ser Phe Val His
115 120 125

Ile Val Gln Met Phe Ile Asn Thr Ser Ser Gly Gly Gly Ser Gly Gly
130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
145 150 155 160

Ser Leu Gln Ile Thr Cys Pro Pro Pro Met Ser Val Glu His Ala Asp
165 170 175

Ile Trp Val Lys Ser Tyr Ser Leu Tyr Ser Arg Glu Arg Tyr Ile Cys
180 185 190

Asn Ser Gly Phe Lys Arg Lys Ala Gly Thr Ser Ser Leu Thr Glu Cys
195 200 205

Val Leu Asn Lys Ala Thr Asn Val Ala His Trp Thr Thr Pro Ser Leu
210 215 220

Lys Cys Ile Arg Asp Pro Ala Leu Val His Gln Arg Pro Ala Pro Pro
225 230 235 240

Ser Thr Val Thr Thr Ala Gly Val Thr Pro Gln Pro Glu Ser Leu Ser
245 250 255

Pro Ser Gly Lys Glu Pro Ala Ala Ser Ser Pro Ser Ser Asn Asn Thr
260 265 270

Ala Ala Thr Thr Ala Ala Ile Val Pro Gly Ser Gln Leu Met Pro Ser
275 280 285

Lys Ser Pro Ser Thr Gly Thr Thr Glu Ile Ser Ser His Glu Ser Ser
290 295 300

His Gly Thr Pro Ser Gln Thr Thr Ala Lys Asn Trp Glu Leu Thr Ala
305 310 315 320

Ser Ala Ser His Gln Pro Pro Gly Val Tyr Pro Gln Gly His Ser Asp
325 330 335

Thr Thr Val Ala Ile Ser Thr Ser Thr Val Leu Leu Cys Gly Leu Ser
340 345 350

Ala Val Ser Leu Leu Ala Cys Tyr Leu Lys Ser Arg Gln Thr Pro Pro
355 360 365

Leu Ala Ser Val Glu Met Glu Ala Met Glu Ala Leu Pro Val Thr Trp
370 375 380

Gly Thr Ser Ser Arg Asp Glu Asp Leu Glu Asn Cys Ser His His Leu
385 390 395 400

<210> 9
<211> 5
<212> PRT
<213> Mus musculus

<400> 9

Arg Tyr Thr Met His
1 5

<210> 10
<211> 17
<212> PRT
<213> Mus musculus

<400> 10

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys
1 5 10 15

Asp

<210> 11
<211> 10
<212> PRT
<213> Mus musculus

<400> 11

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr

1 5 10

<210> 12
<211> 10
<212> PRT
<213> Mus musculus

<400> 12

Ser Ala Ser Ser Ser Val Ser Tyr Met Asn
1 5 10

<210> 13
<211> 7
<212> PRT
<213> Mus musculus

<400> 13

Asp Thr Ser Lys Leu Ala Ser
1 5

<210> 14
<211> 9
<212> PRT
<213> Mus musculus

<400> 14

Gln Gln Trp Ser Ser Asn Pro Phe Thr
1 5

<210> 15
<211> 10
<212> PRT
<213> Mus musculus

<400> 15

Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn
1 5 10

<210> 16
<211> 10
<212> PRT
<213> Mus musculus

<400> 16

Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr
1 5 10

<210> 17
<211> 13
<212> PRT
<213> Mus musculus

<400> 17

Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val
1 5 10

<210> 18
<211> 11
<212> PRT
<213> Mus musculus

<400> 18

Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn
1 5 10

<210> 19
<211> 7
<212> PRT
<213> Mus musculus

<400> 19

Tyr Thr Ser Arg Leu His Ser
1 5

<210> 20
<211> 9
<212> PRT
<213> Mus musculus

<400> 20

Gln Gln Gly Asn Thr Leu Pro Trp Thr
1 5

<210> 21
<211> 119
<212> PRT
<213> Mus musculus

<400> 21

Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser
115

<210> 22
<211> 107
<212> PRT
<213> Mus musculus

<400> 22

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
1 5 10 15

Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala His Phe Arg Gly Ser
50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Gly Met Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr
85 90 95

Phe Gly Ser Gly Thr Lys Leu Glu Ile Asn Arg
100 105

<210> 23
 <211> 122
 <212> PRT
 <213> Mus musculus

<400> 23

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Met Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
 20 25 30

Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Met
 35 40 45

Gly Leu Ile Asn Pro Tyr Lys Gly Val Ser Thr Tyr Asn Gln Lys Phe
 50 55 60

Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95

Ala Arg Ser Gly Tyr Tyr Gly Asp Ser Asp Trp Tyr Phe Asp Val Trp
 100 105 110

Gly Ala Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 24
 <211> 109
 <212> PRT
 <213> Mus musculus

<400> 24

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
 35 40 45

Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Lys Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65 70 75 80

Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95

Thr Phe Ala Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala
100 105

CLAIMS

1. A method for producing a CD3-positive cell, comprising step
(I) of culturing the CD3-positive cell in the presence of a
5 CD3/TCR complex agonist, fibronectin or a variant thereof, and
a CD30 agonist.

2. The method according to claim 1, further comprising step
(II) of culturing the CD3-positive cell cultured in step (I) in
10 the absence of a CD3/TCR complex agonist and fibronectin or a
variant thereof, and in the presence of a CD30 agonist.

3. The method according to claim 1 or 2, wherein the CD3-
positive cell is derived from a pluripotent stem cell.

15

4. The method according to claim 3, wherein the pluripotent
stem cell is an iPS cell.

5. The method according to any one of claims 1 to 4, wherein
20 the CD3-positive cell is a chimeric antigen receptor-expressing
CD3-positive cell.

6. The method according to any one of claims 1 to 5, wherein
the CD3-positive cell is a CD3-positive CD8-positive cell.

25

7. The method according to claim 6, wherein the CD3-positive
CD8-positive cell is a CD3-positive CD8-positive CD4-negative
cell.

30 8. The method according to any one of claims 1 to 7, wherein
the CD3-positive cell is a γ TCR-positive and/or δ TCR-positive
cell.

9. The method according to any one of claims 1 to 8, wherein
35 the CD3/TCR complex agonist is a CD3 agonist and/or a TCR

agonist.

10. The method according to claim 9, wherein the CD3 agonist is an anti-CD3 agonist antibody or a binding fragment thereof.

5

11. The method according to claim 10, wherein the anti-CD3 agonist antibody or a binding fragment thereof is an anti-CD3 agonist antibody or a binding fragment thereof produced from UCHT1 clone.

10

12. The method according to claim 9, wherein the TCR agonist is at least one selected from the group consisting of an anti-TCR antibody or a binding fragment thereof, an HLA/peptide complex or a multimer thereof, and an HLA/superantigen complex or a multimer thereof.

15

13. The method according to claim 10 or 11, wherein the anti-CD3 agonist antibody or a binding fragment thereof is immobilized on a culture container.

20

14. The method according to claim 13, wherein the anti-CD3 agonist antibody or a binding fragment thereof is immobilized by contacting 1 ng/ml - 50000 ng/ml of the anti-CD3 agonist antibody or a binding fragment thereof with the culture container.

25

15. The method according to any one of claims 1 to 14, wherein the fibronectin or a variant thereof is RetroNectin (registered trade mark).

30

16. The method according to claim 15, wherein the RetroNectin (registered trade mark) is immobilized on the culture container.

17. The method according to claim 16, wherein the RetroNectin (registered trade mark) is immobilized by contacting 1 - 150

35

µg/mL of the RetroNectin (registered trade mark) with the culture container.

18. The method according to any one of claims 1 to 17, wherein
5 the CD30 agonist is at least one selected from the group consisting of an anti-CD30 agonist antibody or a binding fragment thereof and a CD30 ligand or a binding fragment thereof.

10 19. The method according to claim 18, wherein the anti-CD30 agonist antibody or a binding fragment thereof is contained in the medium.

20. The method according to claim 19, wherein a concentration
15 of the anti-CD30 agonist antibody or a binding fragment thereof in the medium of 1 ng/ml - 1000 ng/ml.

21. The method according to any one of claims 1 to 20, wherein the medium comprises at least one selected from IL-7, IL-15,
20 IL-18 and IL-21.

22. The method according to claim 21, wherein the medium comprises IL-7, IL-15, IL-18 and IL-21.

25 23. The method according to claim 21 or 22, wherein the medium further comprises TL1A and/or IL-12.

24. The method according to any one of claims 1 to 23, wherein the CD3-positive cell produced is further CD197-positive.

30

25. A CD3-positive cell obtained by the method according to any one of claims 1 to 24.

26. A method for expansion culture of a CD3-positive cell,
35 comprising a step of culturing the CD3-positive cell in the

presence of a CD3/TCR complex agonist, fibronectin or a variant thereof, and a CD30 agonist.

27. A kit for expansion culture of a CD3-positive cell,
5 comprising the following:

- (1) a culture container in which a CD3/TCR complex agonist, and fibronectin or a variant thereof are immobilized, and
- (2) a medium comprising a CD30 agonist.

10 28. A method for maintaining a CD3-positive cell as a CD3-positive CD197-positive cell, comprising a step of stimulating a CD30 signal in the CD3-positive cell.

29. The method according to claim 28, wherein the CD3-positive
15 cell is a CD3-positive CD8-positive cell.

30. The method according to claim 29, wherein the CD3-positive CD8-positive cell is a CD3-positive CD8-positive CD4-negative cell.

20

31. The method according to any one of claims 28 to 30, wherein the medium used in the step of stimulation comprises at least one selected from IL-7, IL-15, IL-18 and IL-21.

25 32. The method according to claim 31, wherein the medium used in the step of stimulation comprises IL-7, IL-15, IL-18 and IL-21.

33. The method according to claim 31 or 32, wherein the medium
30 used in the step of stimulation further comprises TL1A and/or IL-12.

34. A kit for maintaining a CD3-positive cell as a CD3-positive CD197-positive cell, comprising a CD30 agonist.

35

35. A chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain and an intracellular signal transduction domain, wherein the intracellular signal transduction domain comprises a CD30 intracellular signal transduction domain or a mutant thereof.
5

36. A nucleic acid comprising a polynucleotide encoding the chimeric antigen receptor according to claim 35.

10 37. A chimeric antigen receptor expression vector comprising the nucleic acid according to claim 36.

38. A chimeric antigen receptor-expressing cell comprising the chimeric antigen receptor expression vector according to claim 15 37.

39. The cell according to claim 38, wherein the chimeric antigen receptor expression cell is a CD3-positive cell.

20 40. A medicament comprising the cell according to claim 38 or 39.

41. The medicament according to claim 40 for use in the prophylaxis or treatment of a tumor expressing an antigen
25 recognized by the chimeric antigen receptor according to claim 35.

42. An agent for killing a cell expressing an antigen recognized by the chimeric antigen receptor according to claim 30 35, wherein the agent comprises the cell according to claim 38 or 39.

43. The cell according to claim 38 or 39 for use in the prophylaxis or treatment of a tumor expressing an antigen
35 recognized by the chimeric antigen receptor according to claim

35.

44. Use of the cell according to claim 38 or 39 in producing an agent for the prophylaxis or treatment of a tumor expressing an
5 antigen recognized by the chimeric antigen receptor according to claim 35.

45. A method for preventing or treating a tumor expressing an antigen recognized by the chimeric antigen receptor according
10 to claim 35, comprising administering the cell according to claim 38 or 39.